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The injecting drug use and the spread of blood-borne viruses (e.g. human 
immunodeficiency virus (HIV) and hepatitis C virus (HCV)) due to conta-
minated syringes are a major concern worldwide. As of 2012, approximately 35 
million people are infected with HIV and 150 million have persistent HCV 
infection (www.who.int). Despite the fact that 20% of HCV infected persons 
clear the virus spontaneously, HIV infection cannot be resolved by host’s 
immune system.  
However, despite multiple exposures to HIV, some people do not get 
infected and are called thus highly exposed HIV seronegative individuals 
(HESNs). They can be found among intravenous drug users (IDUs) sharing 
needles, haemophiliacs who repeatedly received contaminated blood products, 
infants born to HIV-infected mothers and individuals exposed through HIV 
positive sexual partners. The reasons behind this phenomenon are not fully 
understood and HESNs are under major interest in order to explain the 
resistance against HIV.  
Many factors influence the susceptibility to HIV. The factors are, for 
example, the route of transmission, the viral load of the index subjects, the 
presence of other sexually transmitted diseases and immunological and genetic 
factors of the host. The best known genetic factor is the 32 base pair deletion in 
HIV co-receptor encoding gene (CC chemokine receptor 5) CCR5, which gives 
the resistance to HIV R5-tropic viruses (viruses that use CCR5 as a co-
receptor). Also other polymorphisms in different genes (in targeted gene 
approach or in genome wide association studies) have been identified to 
influence the susceptibility to HIV. The associations between host genetic 
factors and susceptibility to HIV are relatively well described in subjects 
infected through sexual or mother-to-child transmission. Whether these 
associations are present in IDU populations, such as the majority of HIV 
positives in former Soviet Union, including Estonia, is poorly studied. 
In Estonia, the infection rate of HIV and HCV among IDUs is very high 
[Uuskula et al., 2007]. The HCV epidemic started in the early 1990s and the 
HIV epidemic in 2000 when rare recombinant form CRF06_cpx entered into the 
IDUs population (www.terviseamet.ee). The high prevalence of these infections 
is still a problem today. Previous studies and doctoral theses on HIV infection 
in Estonia have mainly concentrated on the epidemiological aspects of the HIV 
epidemic [Rüütel, 2009] and HIV molecular epidemiology including HIV drug 
resistance and vaccine development [Adojaan, 2009; Avi, 2011]. The virus 
circulating in Estonia is relatively well described. However, little research has 
been conducted to evaluate how host genetic factors influence the susceptibility 
to HIV in the population predominantly consisting of subjects infected via 
intravenous drug use. Similarly to HIV in the Estonian HCV epidemic, the 
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characteristics of the virus are described [Žusinaite, 2005; Tallo, 2008] but the 
relationship between host factors and the susceptibility to HCV is unclear.  
Bearing in mind the lack of knowledge of host genetic factors in HIV and 





2. REVIEW OF THE LITERATURE 
2.1. HIV and HCV epidemics in the world 
Approximately 35 million people were infected with HIV in the year 2012, and 
2.5 million new infections occurred in 2011 (www.who.int). The virus causes 
an acquired immunodeficiency syndrome (AIDS), a condition in humans in 
which progressive failure of the immune system allows life-threatening 
opportunistic infections and cancers to appear. Now, when there is relatively 
effective treatment available, the cases of AIDS have dropped in developed 
countries but the HIV epidemic has a major impact in certain regions and risk 
groups. Despite the effective treatment, the virus is persistent for a lifetime with 
some exceptions. There is only limited evidence that HIV could be completely 
eliminated – a case of stem cell transplantation from CCR5-∆32 homozygous 
subjects and in very early treatment initiation in a new born [Allers et al., 2011; 
Persaud et al., 2013]. 
Another virus that shares similar transmission route with HIV (blood borne 
virus) and causes worldwide epidemic is HCV. Over 150 million people have a 
persistent HCV infection being the main cause of acute and chronic liver 
diseases including chronic hepatitis, cirrhosis and hepatocellular carcinoma 
(www.who.int) [Liang et al., 2000]. Acute HCV infection is often asymptomatic 
or with non-specific and mild symptoms. Unlike HIV, up to 20% of HCV 
infected subjects will have spontaneous clearance of the virus, and of the 
remaining, the virus could be eliminated with treatment, however, up to 40% of 
treated persons will not be responsive to the therapy [Alter and Seeff, 2000].  
A major concern is the co-infection with both HIV and HCV. Approximately 
30% of HIV-positive subjects in the United States and Europe are co-infected 
with HCV [Alter, 2006]. The co-infection rate among IDUs is higher and 
exceeds 90% in most studies [Sherman et al., 2002a]. HIV/HCV co-infection 
results in a higher rate of morbidity and mortality of liver diseases. The 
influence of HIV infection on HCV disease includes a higher rate of viral 
persistence and increased HCV viral loads [Cribier et al., 1995; Matthews-Greer 
et al., 2001; Sherman et al., 2002b], a faster rate of progression to fibrosis, 
cirrhosis and hepatocellular carcinoma [Martinez-Sierra et al., 2003; Mohsen et 
al., 2003; Pol and Zylberberg, 1998]. In addition, persons co-infected with 
HIV/HCV have a worse treatment response to interferon-alpha (IFN-α)-based 
therapies compared to HCV monoinfected individuals [Chung et al., 2004; 
Perez-Olmeda et al., 2003; Torriani et al., 2004]. 
The influence of HCV on HIV infection is still arguable. More rapid HIV 
disease progression and an increased risk of progression to AIDS and death in 
HIV/HCV co-infected compared to HIV monoinfected patients have been 
demonstrated [De Luca et al., 2002; Piroth et al., 1998]. However, there is a 
number of studies not finding any correlation between HIV/HCV co-infection 
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and HIV disease progression, the development of AIDS and death [Haydon et 
al., 1998; Rockstroh et al., 2005; Staples et al., 1999; Sulkowski et al., 2002]  
 
 
2.2. HIV and HCV epidemics in Estonia 
In Estonia, the increased rates of HCV infection were highest at the beginning 
of the 1990s (Figure 1). Similar to other areas, the prevalence was especially 
high among IDUs ranging from 76% to 90% [Lõhmus et al., 2008]. Not 
surprisingly, HIV and HCV co-infections are also common – 96% of HIV 
positive IDUs in some areas in Estonia are co-infected with HCV [Uuskula et 
al., 2007]. The main HCV genotypes circulating in Estonia are 1 and 3 from 
which the most prevalent subtype is 1b and in lesser extent subtype 3a 
[Zusinaite et al., 2000; Tallo et al., 2007].  
 
 
Figure 1. The prevalence of HIV, HBV and HCV infection in Estonia. Incidence per 
100,000 population of HIV (red line), HBV (blue line) and HCV (green line) infection 
in Estonia between 1985-2010, as reported by the Estonian Health Board. 
 
The first HIV positive subject in Estonia was diagnosed in 1988, but until 2000 
the prevalence of the infection remained low (under 100 cases). The disease was 
mainly transmitted sexually (homo- or heterosexually) [Ustina et al., 2001]. The 
HIV epidemic suddenly erupted in August 2000 when HIV-1 was introduced to 
the IDUs population (Figure 1) [Laisaar et al., 2011]. After that, the number of 
patients infected with HIV-1 increased rapidly, reaching the highest prevalence 
of 105.3 per 100,000 inhabitants in European Union in 2001. Since 2001, the 
number of new infections is declining but Estonia is still one of the three 
countries in Eastern-Europe and Central Asia in which the estimated HIV 
prevalence is around 1% of adult population [Lai et al., 2009]. 
Contrary to other countries of the former Soviet Union in which subtype A1 
is the most prevalent, the Estonian HIV-1 epidemic is stably caused by the rare 
HIV-1 CRF06_cpx and by its recombinants with the subtype A1 [Avi et al., 
2009; Avi et al., 2010; Zetterberg et al., 2004]. The HIV-1 CRF06_cpx is a 
3
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recombinant form between subtypes A, G, K and J [Montavon et al., 1999; 
Oelrichs et al., 1998]. Before the Estonian outbreak, CRF06_cpx was spreading 
mainly in Mali, Niger and Burkina Faso, and only single strains had been 
described outside of Africa [Mamadou et al., 2002; Montavon et al., 1999; 
Oelrichs et al., 1998]. The routes how the virus was imported to Estonia are not 
defined. 
The HIV epidemic is located in Northern and North-Eastern part of Estonia 
(capital Tallinn and Ida-Viru County, respectively). In the new concentrated 
epidemic in 2000–2001, over two-thirds of the infected subjects were young 
male IDUs (www.terviseamet.ee). This situation remained unchanged during 
the following years until 2009, when the proportion of IDUs started to diminish 
(unpublished data). Still, most new cases have been diagnosed among men 
(68%) and among people under 30 during the past decade [Laisaar et al., 2011]. 
Similar to other countries, the IDU epidemic is slowly moving to the general 
population; according to the Estonian HIV database approximately 50% of HIV 
cases occur among non-IDUs in 2010 (unpublished data). The HIV subtype 
structure, however, has been unchanged during the entire concentrated epidemic 
period [Avi et al., 2013]. 
 
 
2.3. Factors influencing the susceptibility to HIV  
The resistance of HESNs to HIV is not fully understood and these subjects are 
under major interest to explore the reasons between the acquisition of HIV 
infection and host factors, and also other potential factors that could explain the 
resistance to HIV. However, the definition of HESNs is very broad and usually 
the term is defined based on the specific study population. For example, based 
on the various interval of sharing the used needles (receptive sharing) or having 
unprotected sex with HIV-positive subject. However, a number of studies have 
determined the associations between different host and viral factors and the 




2.3.1. The route of transmission and  
the susceptibility to HIV infection 
HIV can be transmitted by sexual, parenteral and mother-to-child route. Sexual 
transmission includes female-to-male, male-to-female and male-to-male 
transmission; parenteral transmission includes the transfusion of the infected 
blood or infected syringes in IDUs. Mother-to-child transmission (MTCT) 
could occur during pregnancy, during labour or postnatally [Galvin and Cohen, 
2004; Royce et al., 1997]. The highest probability to acquire HIV infection is 
via routes that lack the first human defence mechanism – the mucosal barrier 
(e.g. through contaminated blood or syringes) [Shaw and Hunter, 2012]. When 
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infected blood products are used, the likelihood of viral transmission is near to 
100% [Galvin and Cohen, 2004]. However, this route presently is very rare in 
the developed world. Similarly, the transmission rate in subjects using 
intravenous drugs and sharing the needles is very high compared to sexual 
transmission up to 20 times [Galvin and Cohen, 2004]. In addition to parenteral 
transmission, sharing used needles increases the probability of infection because 
the virus can be viable and proliferating up to four weeks depending on the 
storage temperature, the volume of residual blood and the viral load [Abdala et 
al., 1999; Uuskula et al., 2006]. Among sexual routes, the highest risk to get 
infected is unprotected rectal intercourse followed by vaginal and orogenital 
contact [Gray et al., 2001; Hladik and Hope, 2009; Powers et al., 2008; Wawer 
et al., 2005; Winkelstein et al., 1987]. Peripartum and perinatal mother-to-child 
transmission without ARV prophylaxis 25–45% but with prophylaxis can be 
diminished to less than one percent [Galvin and Cohen, 2004]. Several other 
factors such as the presence of sexually transmitted diseases, especially those 
that generate genital inflammation and ulcers, and pregnancy are described to 
increase the susceptibility to HIV infection, whereas circumcision decreases it 
up to 60% [Auvert et al., 2005; Bailey et al., 2007; Galvin and Cohen, 2004; 
Gray et al., 2007].  
 
 
2.3.2. Viral factors associated with the susceptibility  
to HIV infection 
For now there is no clear evidence that HIV-1 viral diversity (subtypes) 
influence HIV-1 transmission. Although the prevalence of CRF01_AE 
increased during 1995 to 1998 compared to subtype B among Thai IDUs 
[Hudgens et al., 2002], it is unclear whether other factors (host and epidemio-
logical) have contributed to that. In Uganda and its neighbouring areas, subtype 
D has shown to have R5/X4 dual tropism more often than other HIV-1 sub-
types, but presumably it does not influence viral transmissibility but rather 
affects viral pathogenesis [Church et al., 2010].  
The HIV viral load of a donor is a major factor influencing its trans-
missibility. Studies on discordant couples have shown that viral load is in a 
positive correlation with the transmission rate and that subjects with plasma 
viral load of less than 1000 copy/mL rarely transmit the virus [Fideli et al., 
2001; Quinn et al., 2000]. It is likely that similar trends are seen in all 
transmission routes. In addition, the stage of HIV infection has been associated 
with the acquisition of HIV. Namely persons with acute infection are more 
likely to transmit the virus than those in the other stages of infection [Brenner et 
al., 2007; Powers et al., 2008; Wawer et al., 2005]. This probably reflects the 




2.3.3. Host factors associated with the susceptibility  
to HIV infection 
The analysis of host factors could be divided into immunological and genetic 
factors.  
 
2.3.3.1. Immune factors associated with the susceptibility  
to HIV infection 
The majority of studies exploring the associations between host immune factors 
and the susceptibility to HIV have been conducted in the sexually exposed HIV 
uninfected subjects (ESNs). Velilla et al (2005) showed in vitro that the 
peripheral blood monocytes of ESNs have a greater potential to undergo 
spontaneous apoptosis as well as HIV induced apoptosis compared with the 
cells of healthy controls [Velilla et al., 2005]. The higher expression of INF-α in 
ESNs as compared to the controls has also been demonstrated because INF-α 
induces apoptosis of CD4+ T cells and inhibits HIV replication [Hirbod et al., 
2006]. In addition, a higher production of INF-γ by innate immune cells (e.g. 
NK cells and CD3+/CD56+ cells) in ESNs compared to healthy controls has 
been suggested to have a controlling effect in sexual and vertical transmission 
[Kuhn et al., 2001; Montoya et al., 2006]. Also, highly exposed IDUs had a 
higher lytic activity of NK cells and NK cells producing INF-γ, tumor necrosis 
factor alpha (TNF-α), CCL3, CCL4 and CCL5 than controls and HIV-1 
seroconverters [Scott-Algara et al., 2003].  
The level of innate soluble factors has been associated with the resistance to 
HIV infection. The level of CCL5 and CCL3 is elevated in cultures of HIV-
specific CD4+ T cells from ESNs compared to healthy controls, and these 
chemokines were able to inhibit the replication of R5-tropic viruses [Furci et al., 
1997]. Through the activation of these chemokines, the CD4+ T cells from 
ESNs were less susceptible to HIV than those from healthy controls[Paxton et 
al., 1996].  
Immune activation is essential to have an effective immune response against 
pathogens including HIV but also to induce the viral replication in infected cells 
[Biasin et al., 2000]. Begaud et al showed a lower number of CD4+HLA-DR+ 
T cells in ESNs compared to healthy controls [Begaud et al., 2006]. This 
suggests that lower immune activation may contribute to HIV resistance. Baisin 
et al (2000) found that CD4+CD28+ and CD4+CD38+ T cells were augmented 
in ESNs compared to the controls. Also they showed that PBMCs from ESNs 
express higher levels of IL-6, IL-10, IL-12, INF-γ, TNF-α, TNF-β mRNA than 
PBMCs from controls. In ESNs, HIV-specific INF-γ-secreting CD8+ T cells in 
cervical vaginal washes were increased compared to controls [Biasin et al., 
2000]. Recently, it has been demonstrated that CCR5 expression on CD4+ T 
cells is higher in HESNs than in unexposed uninfected subjects. In addition, 
HESNs had lower levels of naïve and CD28+ T cells and higher level of HLA-
DR+ T cells compared to unexposed uninfected subjects [Suy et al., 2007]. 
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The resistance to HIV infection is also associated with the production of 
HIV-1 specific immunoglobulin A in cervicovaginal secretions, saliva, serum, 
maternal milk and urethral swabs [Piacentini et al., 2008].  
 
2.3.3.2. Host genetic factors and the susceptibility to HIV infection 
In different association studies, several host genetic factors have been related to 
the risk of HIV infection. As presented in Table 1 the major attention has been 
on CCR5 and its ligands.  
 
Table 1. The associations between chemokines and chemokine receptors and the 
susceptibility to HIV-1 
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The major attention that CCR5 and its ligands has gained is because HIV uses 
CD4 as the main receptor and CCR5 or another chemokine receptor, C-X-C 
chemokine receptor 4 (CXCR4), as the co-receptor to enter into T lymphocytes 
[Berger et al., 1999] (Figure 2). Based on which co-receptor is used, the viruses 
are determined to R5-tropic (using CCR5), X4-tropic (using CXCR4) or R5X4-
tropic (using both co-receptors, also called as dual/mixed tropic) [Berger et al., 
1998]. At the beginning of HIV infection R5-tropic viruses are prevailing.  
 
 
Figure 2. The usage of co-receptor by HIV-1 and main natural ligands for both co-
receptors. The R5-tropic and X4-tropic virus are presented. The CCR5 ligands CCL3, 
CCL3L1, CCL4 and CCL5 (in red on the left panel) and CXCR4 ligand SDF-1 (in 
yellow on right panel) compete with HIV for CXCR4 and CCR5 occupation, 
respectively, blocking HIV entry to the cell (crossed arrow).  
 
The host genetic factors that influence HIV susceptibility are mainly found in 
studies using targeted gene approach, and in lesser extent, in genome wide 
association studies (GWASs) [Limou et al., 2010]. In addition to the genes of 
CCR5 and its ligands, the attention has included also cytokines and HLA 
(Table 2).  
 
Table 2. The associations between different host genetic factors and the 
susceptibility to HIV-1 
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al., 2009] 
AA – African-American; EA – European-American 
Various risk groups – analyses comprised many different transmission routes (mucosal and 
parenteral, except MTCT) and in majority of the cases these routes were combined together not 
analysed separately. 
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2.4. Factors influencing the susceptibility  
to HCV and viral clearance 
The studies of HCV infection have mostly focused on the response to treatment 




2.4.1. The route of transmission and the susceptibility to HCV 
The route of HCV transmission is through blood products – blood transfusion in 
early years and contaminated needles among IDUs at present times [Alter et al., 
1975; Shepard et al., 2005; Wasley and Alter, 2000]. Similar to HIV, the 
percentage of HCV infection (up to 85%) is very high among IDUs [Burt et al., 
2007; Shepard et al., 2005; Tseng et al., 2007]. The possible reason for such 
efficient transmission is the long viability (more than 2 months) of the virus in 
the needles [Paintsil et al., 2010].  
 
 
2.4.2. Viral factors associated with the susceptibility to HCV 
Similar to other blood borne infections, the high viral load is also a significant 
contributing factor in HCV transmission. Compared to HIV, HCV is more 
infectious and thus more easily transmittable. When in IDUs the prevalence of 
HIV is around 60% then in the same population the HCV infection rate may 
reach up to 85% or even higher [Mathers et al., 2008; Nelson et al., 2011]. The 
viral escape mutations are the factors that contribute to HCV persistence so that 
the presence of them may be associated with a delay of the adaptive immune 
response [Bowen and Walker, 2005; Rehermann and Nascimbeni, 2005]. A 
study of two patients infected with the same strain showed that even persons 
sharing several HLA alleles, one person cleared the virus and the other one had 
a chronic infection. The first one had multispecific and vigorous T-cell 
responses but the other had viral mutations in CD8+ T-cell epitope [Tester 
et al., 2005]. Cox et al (2005) showed that no substitutions within CD8+ T-cell 
epitopes were observed in subjects who cleared the virus but substitutions 
existed in 60–75% in subjects who had persistent infection [Cox et al., 2005]. 
 
 
2.4.3. Host factors associated with HCV clearence 
In contrast to HIV infection, HCV can be spontaneously cleared from the 
organism in approximately 20% of the cases [Villano et al., 1999]. HCV 
clearance has been evaluated in several studies. The susceptibility to HCV has 





2.4.3.1. Immune factors associated with HCV clearence 
In acute HCV infection, the HCV-specific CD4+ T cells are important in the 
controlling of the infection, and are crucial in HCV clearance [Diepolder et al., 
1995; Gerlach et al., 1999; Lechner et al., 2000b; Missale et al., 1996; Rosen 
et al., 2002]. Persons who are able to clear the virus have broad and strong  
CD4+ T cell responses, while chronically infected subjects have poor and 
narrow responses [Day et al., 2002; Urbani et al., 2006]. In addition, an 
expression of Th1 cytokine profile from peripheral mononuclear cells (PBMCs) 
from persons with viral clearance, compared to Th2 profile from chronically 
infected persons suggests that Th1 is associated with a successful immune 
response in the early stages of the infection [Folgori et al., 2006; Tsai et al., 
1997; Ulsenheimer et al., 2003]. The accumulation of virus-specific CD8+ T 
cells in the liver has been associated with the transient clearance of viral RNA 
from blood plasma [Cooper et al., 1999; Thimme et al., 2002]. Similar to  
CD4+ T cell responses, a broad and multispecific CD8+ T cell response is asso-
ciated with viral clearance [Cooper et al., 1999; Cox et al., 2005; Cucchiarini et 
al., 2000; Deignan et al., 2002; Durante-Mangoni et al., 2004; Nascimbeni et 
al., 2011; Shoukry et al., 2003; Thimme et al., 2002; Wherry et al., 2003]. 
 
2.4.3.2. Genetic factors associated with HCV clearance  
and/or the susceptibility to HCV 
The host genetic factors are believed to play a crucial role in HCV clearance 
and in some cases also in susceptibility. White American IDUs have higher 
chance to clear HCV than African-Americans [Villano et al., 1999], which 
refers to a genetic variation between these populations. In another study, a 
higher frequency of HCV persistence was observed among non-Hispanic blacks 
compared with non-Hispanic whites or Mexican Americans [Alter et al., 1999]. 
One suggested mechanism behind this phenomenon is the lower INF-γ 
production in the primary infection by African-Americans compared to 
European-Americans [Sugimoto et al., 2003]. No specific genetic factor has 
been found to explain these results but different SNPs have been associated 
with HCV clearance. For example, polymorphisms in 3’ untranslated region of 
2’-5’oligo-adenylate synthetase 1 gene, in the promoter region of dsRNA-
dependent protein kinase, HLA class I genes and haplotypes of inducible nitric 
oxygen synthase gene and IL-10 gene have been associated with HCV clearance 
[Fanning et al., 2004; Knapp et al., 2003a; Knapp et al., 2003b; Mangia et al., 
2004; Oleksyk et al., 2005; Yee et al., 2004]. Additional human genetic factors 
that influence HCV clearance are listed in Table 3.  
In 2009, three GWASs identified SNPs in IL28B gene that were related to 
the outcome of interferon therapy such that the rare variant had a worse 
outcome compared to the common variant [Ge et al., 2009; Suppiah et al., 2009; 
Tanaka et al., 2009]. The same SNPs were showing similar effect on HCV 
clearance [Thomas et al., 2009].  
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Table 3. The associations between host genetic factors and clearance/susceptibility 
to HCV 
Gene SNP/haplotype Effect on susceptibility/ 
viral clearance 
Population or region 
[references]* 
CCR5 rs333 (∆32)  
homozygocity 
Increased risk of HCV Caucasian  
[Woitas et al., 2002] 
CCL3L1 Lower copy number 
than population 
median 
Increased risk of chronic 
HCV 
Caucasian 
[Grunhage et al., 2010] 
IL28B rs12798960C 
homozygocity 





[Pasha et al., 2013; 
Thomas et al., 2009] 
KIR/HLA KIR2DL3/HLA-C1 
homozygosity 




[Zuniga et al., 2009] 
IL-10 –1082A homozygocity Decreased risk of HCV Egyptian 
[Pasha et al., 2013; 
Thomas et al., 2009] 
 –1082G  Spontaneous viral 
clearance 
Argentinean 
[Ramos et al., 2012] 
TGF-β –509T Increased risk of HCV Egyptian 
[Pasha et al., 2013; 
Thomas et al., 2009] 
IL-4  +3C  Spontaneous viral 
clearance 
Argentinean 
[Ramos et al., 2012] 
*In the majority of listed studies the transmission of HCVis unknown, but in general the HCV 
infection has been transmitted by parenteral route 
 
The following chapters will focus on the genetic diversity of chemokine 
receptor CCR5, its ligands CCL3 and CCL5 and TLR3. These molecules play a 
role in HIV entry into the cells and due to that it could be assumed that the 
genes encoding these molecules could interfere to the susceptibility to HIV 
infection. In addition, they are involved in the pathogenesis of HCV infection, 
which is a common co-infection among IDUs, the population where Estonian 
HIV epidemic situates.  
 
 
2.5. Chemokines and chemokine receptors 
Chemokines are chemoattractant cytokines produced by a variety of cell types 
including T cells, macrophages, NK cells, B cells, and masts cells. Chemokines 
are involved in the regulation of cell trafficking to areas of injury and in 
inflammatory and homeostatic processes. The specific effects of chemokines are 
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mediated through members of a family of 7-transmembrane-spanning,  
G-protein-coupled receptors [Murphy, 1994].  
Some chemokine receptors serve as entries to the cell for pathogens like HIV 
that is using CCR5 and CXCR4 as the two main co-receptors for viral entry. For 
that reason the most studied host factors in the context of HIV are with CCR5 
and its ligands. As discussed above, the genetic diversity of CCR5 and its 
ligands CCL3-CCL4 cluster and CCL5 (previously named as RANTES) has 
been demonstrated to influence the susceptibility to HIV and/or the disease 
progression (Table 1).  
 
 
2.5.1. The genetic variability of CCR2-CCR5  
and the susceptibility to HIV infection 
CCR5 gene is located at 3q21.3 and includes two 5’ untranslated exons (Exon1, 
Exon2a and Exon2b) and one exon (Exon3) that contains the entire coding 
sequence [Carrington et al., 1999; Mummidi et al., 1997] (Figure 5). The 
expression of CCR5 is restricted to the activated T cells and memory T cells, 
monocytes/macrophages, microglial cells and, to a lesser extent, B cells [Bleul 
et al., 1997; He et al., 1997; Wu et al., 1996; Wu et al., 1997].  
The best known polymorphism in CCR5 gene is a 32 bp deletion in ORF 
(CCR5-Δ32) that in a homozygote state gives complete resistance to HIV-1 R5 
[Samson et al., 1996]. The prevalence of CCR5-Δ32 allele varies between 
populations being highest in Scandinavian (CCR5-Δ32 homozygocity 2–3% and 
heterozygocity around 20%) and absent in African populations [Novembre et 
al., 2005]. In Estonia, about 3% of populations carries CCR5-Δ32 in the 
homozygous state and 21% in the heterozygous state [Adojaan et al., 2007; 
Kalev et al., 2000]. 
A minor HIV-1 co-receptor CCR2 and CCR5 are separated by only ~14 kb, 
partly explaining the near complete linkage disequilibrium between these two 
genes [Smith et al., 1997]. Polymorphism, a G-to-A transition at position 190, 
changes CCR2B codon 64 from valine to isoleucine, introducing a conservative 
amino acid change into the first transmembrane domain [Smith et al., 1997]. 
Studies have not determined a difference in HIV-1 co-receptor activity between 
the variant CCR2B-64I and CCR2B-64V, and excluded the possibility that 
CCR2B-64I exerts a dominant-negative effect on the expression and the activity 
of CCR5 [Lee et al., 1998; Mariani et al., 1999].  
In addition, several polymorphisms within the CCR5 promoter region and 
one in CCR2 gene have been identified as being associated with the sus-
ceptibility to HIV infection [Gonzalez et al., 1999]. Based on seven SNPs in the 
cis-regulatory region of CCR5 and the presence of the CCR2 V64I and CCR5 
ORF Δ32, nine CCR5 human haplotypes (HH) have been defined by the 
evolutionary analyses [Mummidi et al., 2000] (Figure 3). These CCR5 HH are 
designated as HHA to HHG*2, with HHF*2 and HHG*2 denoting the haplo-
types that bear the CCR2-64I and CCR5-∆32 polymorphisms, respectively. 
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Because of its similarity to the chimpanzee CCR5 sequence, the human CCR5 
HHA haplotype is classified as the ancestral CCR5 haplotype [Mummidi et al., 
2000] (Figure 3).  
 
 
Figure 3. CCR5 polymorphisms and haplotypes. Nucleotide variations relative to the 
ancestral sequence and the CCR5 numbering systems are shown. Top numbering is 
based on GenBank accession numbers AF031236 and AF031237 bottom numbers are 
rs-numbers. Ex – exon; In – intron; ORF – open-reading frame; Wt – wild-type; D32 – 
32-basepair deletion.  
 
Both CCR5 SNPs and haplotypes have been associated with the susceptibility to 
HIV and the disease progression in sexual and MTCT (Table 1).  
 
 
2.5.2. CCL3L1 and the susceptibility to HIV infection 
The cluster of proinflammatory CC chemokines containg 16 genes is localized 
at 17q11.2-q12. The MIP-1α, and MIP-1β were renamed as CCL3 and CCL4. 
Four genes comprise the two closely related, paralogous pairs CCL3-CCL3L 
and CCL4-CCL4L [Modi, 2004] (Figure 4). Both of these pairs share 95% 





Figure 4. Organization of CCL3-CCL4 cluster. Modified from PlosPathogens 
[Gornalusse et al., 2009] 
 
Official symbols for CCL3L genes are CCL3L1, CCL3L2 and CCL3L3 and for 
CCL4L genes are CCL4L1 and CCL4L2. CCL3L1 and CCL3L3 are separate 
genes, but they have three identical exons encoding identical proteins [Menten 
et al., 2002; Modi, 2004], and for that reason, they are denoted together as 
CCL3L1. CCL3L2 is a pseudogene containing a 5’ truncation compared to 
CCL3L1 [Hirashima et al., 1992]. The non-allelic copies of CCL3 and CCL4 
were designated as CCL3L (previously LD78β, AT 464
.
2, GOS19-2) and 
CCL4L (previously LAG-1, AT744
.
2) [Zlotnik and Yoshie, 2000].  
Among all human, chemokine genes CCL3L and CCL4L are present in 
variable copy numbers. Individuals may vary in the total number of CCL3L and 
CCL4L genes and in their individual components. The CCL3L copy number 
varies from 0 to 14 and CCL4L from 0 to 10 and is strongly influenced by 
ethnicity. The highest copy number of CCL3L-CCL4L is in African populations 
(median 6 for CCL3L and 4 for CCL4L) and the lowest in European populations 
(median 2 for both CCL3L and CCL4L) [Colobran et al., 2008; Gonzalez et al., 
2005]. 
Although CCL3, CCL3L, CCL4 and CCL4L bind to CCR5, the CCL3L1 is 
more effective in inducing intracellular Ca
2+
 signaling and chemotaxis through 
CCR5 compared to CCL3. Its binding affinity to CCR5 is higher, and the 
antagonism to HIV-1 entry through CCR5 is greater than CCL3 being also 
better than CCL5 [Aquaro et al., 2001; Menten et al., 1999; Nibbs et al., 1999; 
Xin et al., 1999]. CCL3 and CCL4 are expressed by monocytes/macrophages, T 
and B lymphocytes and dendritic cells (although they are inducible in most 
mature haematopoietic cells). Both of them are potent chemoattractants of these 
cells [Menten et al., 2002]. 
Studies have shown that the higher copy number of CCL3L1 than the 
population median is associated with the decreased risk of HIV infection and 
has a beneficial effect in the disease progression [Gonzalez et al., 2005] (Table 
1). This association was observed in different ethnic groups with various 
transmission routes – MTCT in Africans, sexual transmission in AA, EA and 
Hispanic-Americans, and blood transfusion in Japanese [Gonzalez et al., 2005; 
Kuhn et al., 2007; Meddows-Taylor et al., 2006; Nakajima et al., 2007]. 
However, several studies have not found any associations between the CCL3L1 
copy number and the acquisition of HIV or the disease progression 





2.5.3. The genetic variability of CCL5 and  
the susceptibility to HIV infection 
The CCL5 gene is located in chromosome 17 (17q11.2–q12) and consists of a 
promoter, three exons and two introns [Donlon et al., 1990]. HIV association 
studies have been concentrating mainly on three SNPs in CCL5. Two of these 
SNPs are located in the promoter region (G-471A and C-96G) and one in intron 
(TIn1.1C). The promoter -471A and -96G alleles enhance CCL5 production and 
intron In1.1C allele reduces CCL5 transcription [An et al., 2002; Bai et al., 
2005; Liu et al., 1999; Nickel et al., 2000; Tanaka et al., 2006].  
The CCL5 is an inflammatory chemokine, which mediates chemotactic 
activity in T cells, monocytes, dendritic cells, natural killer cells, eosinophils, 
and basophils [de la Rosa et al., 2003; Roth et al., 1995; Schall et al., 1990].  
The CCL5 SNPs have been associated with the different risk of HIV 
infection in many populations as shown in Table 1.  
 
 
2.6. Toll-like receptors 
TLRs are pattern-recognition receptors that activate innate immune response in 
humans and thus play a key role in immune response [Kawai and Akira, 2011]. 
The human TLRs family consists of 10 members (TLR1–TLR10), which can be 
classified to (i) TLRs that generally locate in intracellular compartment (e.g. 
endosomes) – TLR3, TLR7, TLR8 and TLR9 and (ii) TLRs that typically locate 
on the cell surface – TLR1, TLR2, TLR4, TLR5 and TLR6 [Beutler, 2004; 
Leulier and Lemaitre, 2008; Medzhitov, 2001; West et al., 2006]. Intracellular 
TLRs nucleic acid-based agonists are specialised to recognize viruses, whereas 
cell-surface TLRs detect products (e.g glycolipids, lipopeptides, flagellin), 
which are a part of a variety of organisms (bacteria, parasites and fungi [Kawai 
and Akira, 2006]. The TLR10 plays a role in the innate immune response to 
infection in intestinal epithelial cells [Regan et al., 2013].  
In terms of blood borne infections such as HIV, HCV and HBV, the 
intracellular TLR members (TLR3, TLR7, TLR8 and TLR9) that recognize 
double-stranded RNA (dsRNA) and trigger immune responses against both 
RNA and DNA viruses by stimulating type I INFs and inflammatory cytokines, 
have been suggested to influence the course of these infections [Alexopoulou et 
al., 2001; Matsumoto et al., 2004]. Recently, in addition to TLR7 and TLR9, 
also TLR3 has gathered attention in HIV susceptibility [Breckpot et al., 2010; 
Mandl et al., 2008; Sironi et al., 2012]. It has been suggested that retroviral 
genome dimerises and forms a secondary structure, and it is likely that during 
this process a double-stranded RNA is formed [Greatorex, 2004; Russell et al., 
2004; Watts et al., 2009]. Using a xenotropic murine leukemia virus-related 
virus as a model, Miyauchi et al., (2012) demonstrated that TLR3 is able to 
recognize retroviral genome and thus evoke antiviral response [Miyauchi et al., 
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2012]. For that reason the diversity of TLR3 has recently gained interest in the 
context of HIV infection.  
 
 
2.6.1. The genetic variability of TLR3 and  
the susceptibility to HIV infection 
TLR3 gene is located in chromosome 4 (4q35.1) and contains four exons. In 
European population, TLR3 gene comprises 12 segregating sites (without 
indels) and in exon 4, one non-synonymous mutation (rs3775291 C→T, also 
known as Leu412Phe).  
TLR3 is expressed within the endosomal compartment of conventional 
dendritic cells, macrophages, T lymphocytes, fibroblasts and hepatocytes [Jiang 
et al., 2005; Lang et al., 2006; Muzio et al., 2000; Rudd et al., 2005; Tabiasco et 
al., 2006; Visintin et al., 2001]. In addition, TLR3 is expressed in epithelial cells 
as well as on their surface [Sha et al., 2004; Uehara et al., 2007].  
Accordingly, a TLR3 polymorphism rs3775291 C→T has been associated 
with an increased risk of enteroviral myocarditis and herpes simplex-1 
encephalitis but provides protection against tick-borne encephalitis [Gorbea et 
al., 2010; Kindberg et al., 2011; Zhang et al., 2007]. Recently, a minor allele of 
TLR3 rs3775291 (T) was shown to be associated with the resistance to HIV-1 
infection in the Spanish (exposed by intravenous transmission) and Italian 
cohorts (exposed by sexual transmission) of HESNs such that T homozygosity 
was overrepresented among infected HESNs as compared to healthy volunteers 
[Sironi et al., 2012]. 
 
 
2.7. Associations between CCR5, CCL3L1, CCL5 and  
TLR3 and HCV susceptibility and viral clearance 
In terms of HCV infection, the CCR5 is involved in the complex processes of 
HCV immune response. Studies have suggested that Th1-CCL5-CCR5 system 
might be important in the induction of immunity against HCV and thus 
influences the outcome of chronic HCV infection [Larrubia et al., 2008; 
Zeremski et al., 2007]. It is hypothesised that CCR5 interacts with its ligands to 
promote the recruitment of Th1 expressing cells into the liver and thus mediates 
the clearance of HCV infected hepatocytes [Kusano et al., 2000; Shields et al., 
1999]. In addition, HCV itself down-regulates CCR5 expression via a direct 
interaction of HCV E2 envelope protein with the tetraspanin CD81 [Nattermann 
et al., 2004; Solari et al., 1997]. Nevertheless, HCV core protein and NS5A 
alters CCL5 promoter activity [Soo et al., 2002] resulting in higher levels of 
CCL5. An increased binding of CCL5 to CCR5 decreases CCR5 surface density 
due to receptor internalization [Solari et al., 1997] and possibly through that 
affects the Th1-CCL5-CCR5 system. However, the influence of the genetic 
variation of CCR5 and its ligands is poorly studied. 
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The CCR5-∆32 homozygosity has been associated with the increased risk of 
HCV infection by Woitas et al., 2005 with contrary results from other studies 
[Glas et al., 2003; Poljak et al., 2003; Ruiz-Ferrer et al., 2004]. No other 
associations between CCR5 SNPs and HCV acquisition have been described. 
The presence of G303A (rs1799987) regardless of other mutations (including 
HHE-HHG*2) was more frequent among persons with the sustained virological 
response to interferon-ribavirine therapy than non-responders [Konishi et al., 
2004]. A similar effect has also been demonstrated in patients with HHE 
homozygosity [Dorak et al., 2002].  
The CCL5 polymorphisms have not been correlated with HCV acquisition. 
However, they have been associated with the outcome of HCV treatment. CCL5 
-471A has been associated with less severe hepatic inflammation and milder 
portal inflammation in Caucasians [Hellier et al., 2003; Promrat et al., 2003]. 
The possession of In1.1C and 3’-222C and the combination of  
-471A/In1.1C/3’222C are related to the worse response to interferon-ribavirin 
therapy in patients infected with HCV genotypes 1 and 4 [Wasmuth et al., 
2004].  
The TLR3 polymorphism has been the focus in HCV infection because this 
receptor recognizes also HCV. However, until now no associations between 
TLR3 polymorphisms and susceptibility to HCV chronic infection has been 
found [Askar et al., 2009]. 
 
 
2.8. Summary of literature 
Some individuals who, despite multiple exposures to HIV and HCV 
(hemofiliacs, commercial sex workers, IDUs who share needles etc.), will not 
get infected – they are defined as HESNs. This group of people has been an 
interest of research for a few decades in order to identify factors that influence 
the susceptibility to HIV. The great interest has been focused on the human 
genetic factors such as HIV co-receptor CCR5 and its ligands genes. An 
excellent example of discovery was the identification of ∆32 homozygocity, 
which gives the complete resistance against HIV R5-tropic viruses [Samson et 
al., 1996]. Still, this does not explain the HESNs phenomenon entirely because 
most of them are not CCR5-∆32 homozygots.  
Other polymorphisms in CCR5, its ligands and also other genes have been 
associated with the susceptibility to HIV (Table 1). However, the majority of 
genetic studies have been conducted among populations exposed by hetero- or 
homosexual contact, or children born to HIV-positive mothers, in which the 
transmission rate is much lower than when viruses are directly injected into the 
bloodstream.  
In addition to HIV, IDU populations are often affected by HCV and HBV. 
The CCR5 gene family has also been demonstrated to play a role in HCV 
infection but in a lesser extent. Still, association studies between HCV and 
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genetic factors are mainly conducted in the chronically infected subjects looking 
at the role of genetic factors in response to treatment. Much less attentions is 
paid to the susceptibility to infection or spontaneous clearance, which is 
characteristic to HCV but not to HIV. Taken together, whether or how CCR5 
and its ligands’ polymorphisms influence susceptibility to HIV and/or HCV in 
IDUs is limited or unknown.  
The population of Estonian IDUs (both HIV positive and negative) gives a 
unique opportunity to explore these associations for several reasons. Firstly, 
Estonian IDUs are homogeneous – relatively young, Caucasian, males co-
infected with HCV [Uuskula et al., 2007]. Secondly, they are infected with 
monophyletic HIV-1 CRF06_cpx viruses, which provide the possibility to 
evaluate associations between host genetic factors and the susceptibility to HIV 
with minimal viral heterogeneity [Avi et al., 2011; Avi et al., 2009; Avi et al., 
2010; Zetterberg et al., 2004]. Thirdly, the high prevalence of HCV enables 
investigations in the associations between host genetic factors and HCV and/or 
HIV/HCV co-infection.  
As described above, CCR5 with its ligands are playing a crucial role in HIV 
infection participating in the viral entry into cells. In addition, CCR5 and its 
ligands are involved in the course of HCV infection, and TLR3 interacts with 
these viruses by recognising HCV and probably also HIV. Thus, this thesis 
concentrates on the associations between CCR5 and its ligands (CCL3L1 and 










3. AIMS OF THE RESEARCH 
The general aim of this thesis was to assess the associations between host genes 
encoding innate and adaptive immunity, and the acquisition of HIV and/or co-
infection with HCV in the IDUs of Caucasian origin.  
 
The study had the following objectives:  
 To identify whether and how the CCL3L1 gene copy number is associated 
with the susceptibility to HIV and/or HCV infection among IDUs  
2.
 To determine whether and how CCR5 haplotypes/haplotype pairs are related 
to the susceptibility to HIV and/or HCV infection among IDUs
  
1.
3. To determine whether and how CCL5 haplotypes/haplotype pairs are related 
to the susceptibility to HIV and/or HCV infection among IDUs  
4. To evaluate whether and how TLR3 polymorphisms are associated with the 




4. MATERIALS AND METHODS 
Altogether, the thesis included four studies conducted in Tallinn and Ida-Viru 
County in 2006 and 2007, and in Tallinn in 2010. These two regions are the 
epicentres of Estonian HIV epidemic. Two cross-sectional studies were 
conducted in two syringe exchange programmes and in three Estonian prisons 
in 2006 and 2007, and in one syringe exchange programme in 2010. The studies 
are detailed in Table 4. 
 
 
4.1. Study design and population 
All studies were conducted in IDUs populations and two recruitments were 
used – one for CCL3, CCL5 and CCR5 studies and another for TLR3 study 
(Table 4). Subjects in the syringe exchange programmes were recruited by using 
respondent driven sampling (RDS) [Malekinejad et al., 2008].  
RDS is a sampling method for the recruitment of most-at-risk populations 
(hidden populations) for behavioural and biological HIV studies. It is a chain-
referral sampling that begins with a specifically selected set of individuals 
(called seeds) from the target population. The seeds will recruit subjects from 
their social network (recruited participants) who will recruit the next ones. 
Seeds and recruited participants will be interviewed and, if necessary, biological 
samples are collected. The process of recruitment produces several waves of 
recruits and finally the subjects will reach to the equilibrium, which indicate 
that final samples are not biased by the selection of seeds.  
In the current thesis, two RDS were conducted and in both six seeds were 
used. The recruitment of IDUs was conducted by the Department of Public 
Health in the University of Tartu and Estonian National Institute for Health 
Development. In addition, subjects were recruited from prisons and were invited 
by their treating physician.  
All study subjects donated blood and filled in a questionnaire that included 
demographic data (date of birth, gender, nationality, risk behaviours, route of 
transmission and duration of IVDU). The subjects recruited in the syringe 
exchange programmes admitted an active use of intravenous drugs. The subjects 
from prisons were determined as IDUs if the previous use of intravenous drugs 
was reported. The duration of IVDU was defined as time (in full years) between 
the first episode of using intravenous drugs and the date of data collection. The 
truncated age and the duration of IVDU were measured in full years.  
The blood donors were recruited in Tallinn and Ida-Viru County in 2010. In 
total, the blood sample leftovers of 500 (all HIV, HBV and HCV negative) 
blood donors were collected so that half of them were from Tallinn and half of 





Table 4. The characteristics of the study populations of the thesis and the suc-









No of IDUs/blood 
donors 
Primary aim Publi-cation 
CCR5 
study 









To determine the 
associations between 
CCR5 haplotypes 






To evaluate the 
associations between 
CCL3L1 copy 






To determine the 
associations between 
CCL5 haplotypes 





IDUs from syringe 
exchange programmes 





To determine the 
associations between 
TLR3 variability and 
susceptibility to HIV 
3 
There was two recruitments (second column) – one indicated in grey and another colourless; 
ND – not done 
In the TLR3 study, 173 of 345 IDUs were HIV seronegative; 88 of them 
reported using previously used syringes (receptive sharing) and 85 did not admit 
to the repetitive usage. Latter were called unexposed and were excluded from 
further analysis. The median of receptive sharing was at least once a month. 
Based on that, the HESNs were defined as IDUs who had shared syringes at 
least once a month during last six months (n = 20) and non-HESNs as those 
who has shared syringes less frequently (n = 68).  
Based on similar categories, the sub-groups of HCV seronegative IDUs were 
determined. HCV negative highly exposed IDUs were defined as IDUs who 
were HCV seronegative, and reported receptive sharing at least once a month 
during last six months. HCV negative non-highly exposed were defined as 
IDUs who were HCV seronegative, and reported receptive sharing less than 




4.2. Ethical consideration 
All study protocols have been approved by the Tallinn Medical Research Ethics 
Committee and/or the Research Ethics Committee of the University of Tartu 
and the University of Texas Health Science Center in San Antonio. All subjects 
signed an informed consent. Blood donors agreed with using their blood 
leftovers anonymously for research purposes. 
 
 
4.3. Blood sampling and processing 
 
4.4. HIV, HBV and HCV antibody testing 
HIV antibody testing was performed in the Estonian Central HIV Reference 
Laboratory using a fourth generation enzyme-linked immunoassay (Vironistica 
HIV Uniform II Ag/Ab, BioMerieux, Marcy Etoile, France); all positive results 
were confirmed by an immunoblotting assay (INNO LIA HIV I/II Score 
Westernblot, Microgen Bioproducts Ltd, Surrey, UK). HCV and HBV antibody 
and antigene testing was performed in the laboratory of the Estonian National 
Institute for Health Development. The presence of HCV antibodies was tested 
with the ETI-AB-HCVK-3 anti-HCV test (DiaSorin, Vercelli, Italy). HBV 
seropositivity was assessed by ETI-MAK-4 HBsAg (DiaSorin, Saluggia, Italy) 
and ETI-AB-COREK Plus (anti-HBc core) (DiaSorin, Saluggia, Italy). 
From all study subjects, except blood donors, appoximately 8–16 ml blood was 
taken via venepuncture into EDTA tubes (BD Diagnostics, New Jersey, NJ, 
USA) in the syringe exchange programmes and prisons. The samples were 
transported to our laboratory in the Department of Microbiology in the 
University of Tartu within 24 hours and were centrifuged at 3000 rpm for 
10 min. Plasma was extracted and divided into several aliquots and stored at  
–80 oC. The remaining fraction (cell fraction) of the sample was also divided 
into the aliquots and stored at -80 oC for DNA extraction.  
The leftover blood samples (approximately 2 ml) of the blood donors were 
collected into EDTA tubes (BD Diagnostics, New Jersey, NJ, USA), stored at 
+4 oC and after confirming their negativity of all three infections they were sent 
to our laboratory in the Department of Microbiology in the University of Tartu 
and stored at -80 oC for DNA extraction.  
The genomic DNA was extracted from 200 µl of the stored cell fraction or 
of the whole blood using the QIAamp DNA Mini Kit (Qiagen, Hilden, 
Germany) as recommended by the manufacturer. The DNA quality and quantity 
were assessed by NanoDrop 3000 (Thermo Fisher Scientific Inc., Waltham, 
MA, USA) and DNA was stored at -80 oC.  
In the CCL3L1 study, the genomic DNA from cell line A431 (courtesy of 
professor Ismo Virtanen, University of Helsinki, Institute of Biomedicine) were 
extracted using the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) as 
recommended by the manufacturer. 
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4.5. The determination of CCL3L1 gene copy number 
The determination of CCL3L1 gene copy number was performed in the Depart-
ment of Microbiology, University of Tartu by Maarja Sadam [Sadam, 2008]. 
CCL3L1 gene copy number was estimated as described by Gonzalez et al (2005).  
Real-time PCR was carried out on ABI/PRISM 7500 Sequence Detector 
System detecting the emitted FAM from the probe for CCL3L1 and VIC from 
the probe for the β-globin during amplification. Real-time PCR was performed 
in 50 µL using 1x Universal Master Mix, 0.25 nM of appropriate probe, 0.3 nM 
of appropriate primer pairs and 2–10 ng genomic DNA and the following 
programme on ABI/PRISM 7500: 50 °C for 2 min, 95 °C for 10 min and 40 
cycles of 95 °C for 15 sec, 60 °C for 1 min. The primers and probes for CCL3L1 
and for β-globin are presented in Table 5. The primers were purchased from 
TAGC (Copenhagen, Denmark) and the rest of the reagents from Applied 
Biosystems (Carlsbad, CA, USA). 
The cycle number at which the fluorescence reached a fixed threshold [cycle 
threshold (Ct)] was determined. Six serial 1:2 dilutions (20–0.625 ng/reaction) 
of A431 cells genomic DNA (having two copies of CCL3L1 per diploid 
genome) were used to generate standard curves of Ct value for β-globin and 
CCL3L1 gene. For each test sample, the β-globin and CCL3L1 were amplified 
in duplicate and the Ct was determined and converted into template quantity 
using the standard curves. For every individual sample the intervariability was 
assessed by formula: Vi(%) = 100*|(Ri1–Ri2)/Ri| where Vi was the sample 
intervariability, Ri1 and Ri2 the sample i quantity and Ri the mean of duplicates. 
All samples where intervariability was more than 15% were reanalysed by the 
real-time PCR. CCL3L1 copy number was the ratio of the mean template 
quantity for CCL3L1 (RiCCL3L1) to the mean template quantity for β-globin 
(Riglob) multiplied by two [CCL3L1 copy number = RiCCL3L1/ Riglob*2]. 
Afterwards, the CCL3L1 copy number was rounded to integer.  
 
 
4.6. The determination of CCR5, CCL5 polymorphisms  
and haplotypes and TLR3 polymorphism  
The determination of CCR5 and CCL5 SNPs were performed in the prof Sunil 
K Ahuja’ laboratory in the Departments of Medicine, University of Texas 
Health Science Center, San Antonio, Texas, USA. Seven SNPs in CCR5 and the 
presence of CCR2-V64I and CCR5-32, three SNPs in CCL5 and one SNP in 
TLR3 were determined using TaqMan Allelic Discrimination assay (Table 5). 
The real-time PCR was performed in 8 µL using 1x Universal Master Mix, 0.25 
nM of appropriate probe, 0.3 nM of appropriate primer pairs or SNP assays and 
approximately 2–5 ng genomic DNA. The sequences of primer and probes are 
listed in Table 6. The real-time PCRs were carried out on ABI/PRISM 7900 
Sequence Detector System using the following programme: 50 °C for 2 min, 
95 °C for 10 min and 45 cycles of 95 °C for 15 sec, 60 °C for 1 min. All 
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reagents were from Applied Biosystems (Carlsbad, CA, USA). Custom made 
real-time PCR primers and probes are designed by professor Ahuja’s laboratory 
at the University of Texas Health Science Center at San Antonio. 
 
Table 5. Primers and probes used in the studies 
Gene or gene 
and SNP  
(rs-number)  
Refs 
Primers and sequences 
(5’→3’) 

































































































Table 5. Continuation 
Gene or gene 
and SNP  
(rs-number)  
Refs 
Primers and sequences 
(5’→3’) 





Commercial probes and primers (Applied Biosystems) 
CCR5 C630T 
(rs41469351) 
















































































Custom made probes and primers (Applied Biosystems)
 #
 
TLR3 rs3775291 Commercial probes and primers (Applied Biosystems) 
*RFLP-PCR was carried out as described in Gonzalez et al (2005); # designed in the prof Sunil K 
Ahuja’ laboratory in the Departments of Medicine, University of Texas Health Science Center, 
San Antonio, Texas, USA (sequences available upon request). 
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The CCR5 haplotypes were defined as shown in Figure 5 [Gonzalez et al., 1999; 
Mummidi et al., 2000]. In CCL5 three SNPs were detected – G-471A 
(rs2107538) and C-96G (rs2280788) in the promoter region and TIn1.1C 
(rs2280789) in intron. We focused on there variations as various previous 
studies had indicated the role of these polymorphism on HIV susceptibility 
and/or CCL5 expression (Table 1) [An et al., 2002; Bai et al., 2005; Liu et al., 
1999; Nickel et al., 2000; Tanaka et al., 2006]. Additionally, these three SNPs 
are located in one haploblock based on the genotype data from Caucasian 
population from HapMap.org (Figure 5).  
 
 
Figure 5. The location of CCL5 rs2107538, rs2280788 and rs2280789 (indicated in 
red circles) in the haploblock according to Haploview analysis in Caucasian 




Using HaploView programme, four CCL5 haplotypes (A to D) were defined by 
these 3 SNPs in Caucasian population as demonstrated in Figure 6. The similar 
haplotypes were also identified from other populations previously (named 




Figure 6. Schematic figure of CCL5 single nucleotide polymorphisms and CCL5 
haplotypes. On the upper panel schematic figure of CCL5 gene with chromosomal 
location and positions of SNPs with rs-numbers are shown. In the table, letters in three 
right side columns indicate nucleotide. 
 
 
4.7. Statistical analysis 
The Pearson’s goodness-of-fit chi-square (degree of freedom = 1) was used for 
the analyses of the Hardy-Weinberg equilibrium. STATA 6.0 (Stata 
Corporation, College Station, Texas, USA) was used for the statistical analyses 
in the CCL3L1 study, the programme R versions 2.8.1 (www.r-project.org, last 
accessed 1
st
 of July, 2011) was used in the CCR5 study and 2.13.1 (www. 
r-project.org, last accessed 1
st
 of January, 2012) in the TLR3 and CCL5 study. 
The differences in the CCL3L1 gene copy numbers between the study 
groups were assessed by the Chi-square tests. The distribution of TLR3 
rs3775291 and CCR5 and CCL5 haplotypes between the study groups were 
evaluated by the Fisher’s exact tests. Next, the univariate and multivariate 
logistic regression analyses were performed. The univariate logistic regression 
analyses were used to determine (i) the associations between host genetic factors 
(CCL3L1 gene copy number, CCR5 and CCL5 haplotypes and TLR3 T allele) and 
HIV or HCV serostatus; (ii) the associations between co-variates (age, gender, 
HCV and HBV infection and the duration of IVDU) and HIV or HCV serostatus. 
The multivariate logistic regression models were used to determine the 
independent effects of the host genetic factors and HIV or HCV serostatus.  
In the CCL3L1 study, in addition to the abovementioned analyses the 
following analyses were carried out. Step-wise multivariate logistic regression 
models were conducted to analyse associations between CCL3L1 copy number 
and HIV and HCV serostatus. In these analyses, CCL3L1 copy number and co-
variates were included sequentially. Interactive multivariate logistic regression 
models were built to assess the interactions between the duration of IVDU and 
CCL3L1 copy number.  
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5. RESULTS AND DISCUSSION 
The overview of the recruited and successfully genotyped subjects is presented 
in Table 5. The rates of successful genotyping were: 100% for CCL3L1, CCR5 
A29G (rs2856758), CCR5 G208T (rs2734648), CCR5 G303A (rs1799987), 
CCR5 T627C (rs1799988) CCR5 C630T (rs41469351), CCR5 C927T 
(rs1800024) and CCR5 Δ32 (rs333); 99.7% for CCL5 C-96G (rs2280788); 
99.6% for TLR3 rs3775291; 99.5% for CCR2 V64I (rs1799864), CCR5 A676G 
(rs1800023), CCL5 G-471A (rs2107538) and CCL5 TIn.1.1C (rs2280789). All 




5.1. The effect of chemokine receptor and chemokine 
polymorphisms on HIV and HCV serostatus 
These studies describe the distribution of CCR5 and CCL5 haplotypes and 
CCL3L1 gene copy numbers and the associations between CCR5/CCL5 
haplotypes, CCL3L1 gene copy numbers and HIV and/or HCV serostatus. 
 
 
5.1.1. Population characteristics in CCR5, CCL3L1  
and CCL5 studies 
As shown in Table 6, the study population was relatively young and 
predominantly male. Approximately half of the subjects were HIV seropositive 
and three-quarters were HCV seropositive.  
 








Age in years, median (IQR) 26 (22–29) 
Duration of IVDU (years), median (IQR) 8 (4–12) 
HIV seropositive, n (%) 208 (56) 
HCV seropositive, n (%) 285 (76) 
HBV seropositive, n (%) 56 (15) 
aIn CCR5 and CCL5 study, 373 persons were in the study population.  
bThe population consists of IDUs from the syringe exchange programmes and from prisons.  
IQR – interquartile range 
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The details of the distribution of HIV, HCV and HBV serostatus are presented 
in Table 7. There were 27% and 7% of subjects HCV or HIV monoinfected, 
respectively. Approximately one-third (35%) was dually infected with HIV and 
HCV and 12% were seropositive for HIV, HCV and HBV. 
 
Table 7. HIV, HCV and HBV serostatus among IDUs 
HIV HCV HBV 
Total = 374 
n (%) 
+ + + 44 (12%) 
+ + – 133 (36%) 
+ – + 4 (1%) 
– + + 8 (2%) 
+ – – 27 (7%) 
– + – 100 (27%) 
– – + 1 (0%) 
– – – 56 (15%) 
 + seropositive; – seronegative 
 
Altogether, 27% of subjects were from prisons and the rest from the syringe 
exchange programme. As presented in Table 8, IDUs from prisons and the 
syringe exchange programmes were similar in terms of gender, age and the 
prevalence of HCV seropositivity. From prison, only HIV positive subjects 
were recruited. 
 
Table 8. The IDUs populations recruited in CCR5, CCL3L1 and CCL5 study – 
prison vs. syringe exchange programmes 
 IDUs from 
prisons 
 
N = 103 
IDUs from  
syringe exchange 
programmes 
N = 270 
p-value 
Age in years, median (IQR) 25.5 (22–29.5) 26 (22–29) 0.821 
Males, % 79.6 86.3 0.152 
HIV seropositive, % 100 38.9 p<0.001 
HCV seropositive, % 70.0 78.5 0.108 
 
As expected in the IDU population, the presence of HCV and HBV was 
associated with the HIV seropositivity and the presence of HIV and HBV with 
the HCV seropositivity (Table 9). The duration of IVDU was associated with 
the HCV or HIV seropositivity, each additional year of IVDU increased the 
odds of HCV and HIV seropositivity. Age and gender did not affect HIV 
serostatus but gender was associated with HCV serostatus such that females had 
lower odds of acquiring HCV infection.  
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42 
Table 9. The associations between co-variates and HCV or HIV serostatus in an 












 1.0   1.0   







 1.0   1.0   




NA   1.0   




 1.0   NA   




 1.0   1.0   
HBV+ 5.10 2.42–10.75 <0.001 3.57 1.38–9.25 0.009 




 1.0   1.0   
Increase with 
each year 
1.08 1.01–1.15 0.025 1.24 1.13–1.36 <0.001 
* – reference group 
a The table represents the associations between co-variates and HIV or HCV infection among 374 
IDUs. 
b The age is splitted on the median of 26 years. 
c Continuous variable in full-years. Reference is one year, every additional year gives 1.08 and 
1.23 times odds of acquiring HIV or HCV, respectively. 
d This association was significant only in CCL3L1 study. 
OR – odds ratio; CI – confidence interval; p – significance value, NA – not applicable 
 
 
5.1.2. The distribution of CCR5 haplotypes and  
haplotype pairs in IDUs and blood donors  
The distribution of CCR5 haplotypes between IDUs and blood donors was 
similar (Figure 7). The most prevalent CCR5 haplotype was HHE (56.4% in 
blood donors and 55% in IDUs) followed by HHC (46.6% and 49.3%, respec-




Figure 7. The distribution of CCR5 haplotypes in blood donors and IDUs. The bars 
show the percentage of IDUs who carry at least one specific CCR5 haplotype. Blue bars 
indicate the blood donors and red bars the IDUs.  
 
In total, the 22 different CCR5 haplotype pairs were present, of which 
HHC/HHE was most prevalent in both populations (Figure 8). The overall 




Figure 8. The distribution of CCR5 haplotype pairs in blood donors and IDUs. Blue 
bars indicate the blood donors and red bars the IDUs. Haplotype pairs are presented 
without HH. 
 
The relatively high frequency of HHG*2 (∆32 bearing haplotype; ~20%) 
(Figure 7) is characteristic for North-European, especially Scandinavian, 
populations [Libert et al., 1998]. In our study, the prevalence of CCR5-∆32 
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homozygosity was 1.1% (95% CI 0.3% – 2.8%) and 1.4% (95% CI 0.6% – 
2.9%) (Figure 12, G2/G2) and heterozygosity 19.3% (95% CI 15.3% – 23.6%) 
and 20.1% (95% CI 16.6% – 23.8%) in IDUs and blood donors, respectively. 
Our results on CCR5-∆32 homozygocity were comparable to the previous 
Estonian study where the prevalence of CCR5-∆32 homozygocity was 3.2% 
(95% CI 1.8% – 5.1%) [Kalev et al., 2000]. The CCR5-∆32 heterozygocity was 
similar in our and in Kalev et al (2002) study (23.2%; 95% CI 19.6% – 27.1%). 
The fact that the frequency of CCR5-∆32 homozygosity is the highest in 
Northen Europe is well described and that there is a North to South gradient is 
also known; the frequency is around 3% in Scandinavia, 2% in France, Italy 1% 
and less than 1% in Spain [Libert et al., 1998; Lucotte and Mercier, 1998]. The 
CCR5-∆32 in the homozygous state is absent in the African populations 
[Philpott et al., 2003]. Consistent with other studies on Caucasian populations, 
the HHB and HHD were not observed by us in Estonian populations [Gonzalez 
et al., 1999; Gonzalez et al., 2001].  
 
 
5.1.3. Associations between CCR5 haplotypes and HIV serostatus 
Of all CCR5 haplotypes, only the frequency of HHF*2 was different between 
HIV seropositive and HIV seronegative IDUs being over-represented in latter as 
compared with the former (23.5% vs 15.0%; p<0.05). The univariate logistic 
regression showed that persons with HHF*2 had 1.8 times reduced odds for 
HIV seropositivity (OR = 0.57, 95% CI 0.34–0.98, P=0.041) than those without 
HHF*2 suggesting a beneficial role of HHF*2 in the susceptibility to HIV 
infection. However, after the adjustment for co-variates (HCV and HBV 
serostatus, the duration of IVDU) or other CCR5 haplotypes the association did 
not remain significant (OR = 0.65; 95% CI 0.34 – 1.24).  
The possession of HHF*2 protected the Kenyan and the Argentinean but not 
the Malawian children of MTCT of HIV [Mabuka et al., 2009; Mangano et al., 
2001; Pedersen et al., 2007]. Furthermore, HHF*2 has been related with the 
decelerated progression of HIV infection to AIDS and preventing death in 
heterosexually infected African American adults and in perinatally infected 
children [Gonzalez et al., 1999; Ioannidis et al., 2001; Malhotra et al., 2011; 
Mangano et al., 2001; Mangano et al., 2000].  
Despite the abovementioned findings, the role of HHF*2 in HIV infection is 
still controversial. There are a number of studies in various populations (mainly 
infected via heterosexual route) in which no associations between HHF*2 and 
the susceptibility to HIV/AIDS has been found [Hladik et al., 2005; Kageyama 
et al., 2001; Nguyen et al., 2004; Pedersen et al., 2007; Ramaley et al., 2002; 
Tan et al., 2010]. Furthermore, there is a study in which the detrimental effect of 
HHF*2 was detected [Ma et al., 2005]. In that study, CCR2-V64I allele (i.e. 
HHF*2) increased the risk of HIV seropositivity among men but not among 
women in Cameroon. Previous studies together with our data indicate that the 
45 
effect of HHF*2 is likely not independent and may depend on other factors such 
as population characteristics, the route of transmission and co-infections.  
Consistent with previous studies, the CCR5-∆32 homozygotes (HHG*2/ 
HHG*2) were found only in HIV negative subjects [Dean et al., 1996; Samson 
et al., 1996], but after the adjustment for co-variates (HCV, HBV serostatus, the 
duration of IVDU) it did not remain significant. 
 
 
5.1.4. CCR5 haplotypes and HCV serostatus 
At first we analysed the associations between CCR5 haplotypes and HCV 
serostatus, which was followed by the analyses of CCR5 halpotypes and 
HIV/HCV co-infection. Finally, we included the haplotype pairs.  
Comparing the distribution of CCR5 haplotypes among HCV seropositive vs 
HCV seronegative IDUs, we observed that the only haplotype overrepresented 
in HCV seronegative compared with HCV seropositive subjects was HHG*1 
(20.7% vs. 7.5%; p<0.001). In the univariate analysis, the possession of HHG*1 
was associated with the decreased odds of HCV seropositivity (Table 10). In the 
multivariate logistic regression analyses, after including all other CCR5 
haplotypes and for co-variates (HIV and HBV serostatus, the duration of IVDU) 
into the analyses, the possession of HHG*1 remained associated with the 
reduced odds of HCV seropositivity compared with those lacking this haplotype 
(Table 10). The HIV and HBV serostatus and the duration of IVDU were 
included as co-variates because they were associated with HCV serostatus 
(Artcle 2, Table 2).  
 
Table 10. Associations between CCR5 HHG*1 and HCV seropositivity before and 
after the adjustment for other CCR5 haplotypes and co-variates compared with 
CCR5 non-HHG*1 
Variable
a Outcome: HCV seropositivity 
OR (95% CI; p) 
1. HHG*1 0.37 (0.17–0.84; 0.017) 
2. HHG*1 
adjusted for all other CCR5 haplotypes 
0.37 (0.16–0.82; 0.015) 
3. HHG*1 
adjusted for HIV and HBV serostatus and the 
duration of IVDU
 
0.07 (0.03–0.20; <0.0001) 








5.1.5. CCR5 haplotypes and HIV/HCV co-infection 
Bearing in mind the significant correlation between HCV and HIV serostatus 
(Table 9), we conducted an analysis between HHG*1 and HIV/HCV co-
infection status where the co-infection with HIV was included as a potential 
confounder. We evaluated the distribution of HHG*1 according to HCV and 
HIV serostatus. As presented in Figure 9, the CCR5 HHG*1 was significantly 
over-represented in subjects who were both HIV and HCV seronegative 
compared with subjects who were HCV seropositive only, HIV seropositive 
only or were dual seropositive (HIV+ and HCV+).  
 
 
Figure 9. The distribution of CCR5 HHG*1 in IDUs population stratified by 
HIV/HCV co-infection status. Red indicates IDUs who carry at least one HHG*1 
allele and blue indicates IDUs who do not carry HHG*1. 
 
After controlling co-variates (the duration of IVDU, HBV, CCL3L1 copy 
number) in individuals who were both HCV and HIV seronegative (reference 
group), the odds of possessing a HHG*1 was decreased by 12 times (OR = 
0.08; 95% CI 0.02–0.29) and six times (OR = 0.18; 95% CI 0.06–0.54) in IDUs 
who were HCV monoinfected, and HCV/HIV dual-infected, respectively 
(Article 2, Table 3, models 1 and 3) suggesting that HHG*1 mainly influences 
the susceptibility to HCV. 
We did not analyse CCR5 HHF*2 because it was not significant in the 





5.1.6. CCR5 HHG*1-containing haplotype pairs and  
HCV serostatus 
Next we determined which specific HHG*1-containg haplotype pair contributed 
to the reduced seropositivity of HCV. We evaluated two of the most common 
HHG*1-containing haplotype pairs – HHE/HHG*1 and HHC/HHG*1 (Figure 
8). Of these, HHE/HHG*1 was more prevalent among the HCV seronegative 
than among the HCV seropositive IDUs (22.5% vs 2.6%; p<0.001). The odds of 
being HCV seropositive were decreased in IDUs who carried HHE/HHG*1 
(OR = 0.11; 95% CI 0.04–0.29) compared with IDUs not having this haplotype 
pair. This association remained significant after the adjustment for co-variates 
(the duration of IVDU, HBV, CCL3L1 copy number) (OR = 0.02; 95% CI 
0.00–0.16). 
In the context of co-infections, the HHE/HHG*1 was over-represented in 
subjects who were seronegative for both HIV and HCV compared with subjects 
who were seropositive for HCV and/or HIV (Figure 10). After controlling the 
same co-variates (the duration of IVDU, HBV, CCL3L1 copy number), the odds 
of possessing HHE/HHG*1 was decreased 50 and 14 times in IDUs who were 
HCV monoinfected (OR = 0.02; 95% CI 0.00–0.20 and OR = 0.07; 95% CI 
0.01–0.32) and HCV/HIV dual-infected, respectively, compared with IDUs who 
were seronegative for both HIV and HCV. The odds of the possession of 
HHE/HHG*1 was not significant comparing HIV monoinfected IDUs with 
HIV/HCV dualnegative IDUs (Article 2, Table 3, models 4 and 6). 
 
 
Figure 10. The distribution of CCR5 HHG*1-containing haplotype pairs in IDUs 
and blood donors (named as Ctr.). Blue indicates the IDUs who do not carry HHG*1 
in either allele, red indicates the IDU carrying HHC/HHG*1, green indicates the IDUs 
carrying HHE/HHG*1 and purple indicates the IDUs who carry CCR5 haplotype pair 
that consists of HHG*1 and other haplotype (except HHC or HHE). 
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5.1.7. CCR5 HHG*1 and HHE/HHG*1 in HCV and  
HIV seronegative IDUs vs. blood donors 
The abovementioned findings showed that HHG*1 (including HHE/HHG*1) is 
associated with the resistance of acquiring HCV or HCV/HIV infection in 
IDUs. Based on that, the prevalence of HHG*1 or HHE/HHG*1 among 
HCV/HIV double negative IDUs should be over-represented compared with 
blood donors. These analyses showed that the prevalence of HHG*1 was 26.3% 
vs. 7.4% (p<0.0001) comparing HCV/HIV double negative IDUs to blood 
donors, respectively, and HHE/HHG*1 haplotype pair 24.6% vs 2.0% 
(p<0.0001; Figure 10). 
To the best of our knowledge, the associations between CCR5 haplotypes 
and HCV infection have been poorly studied despite the role of CCR5 in the 
pathogenesis of HCV infection. Previously, the study by Woitas et al., (2005) in 
patients with haemophilia demonstrated that subjects with CCR5-∆32 
homozygocity (HHG*2/HHG*2) had an increased risk of HCV infection 
compared to healthy controls and HIV and HCV/HIV infected subjects. In this 
study, we and others [Glas et al., 2003; Poljak et al., 2003; Ruiz-Ferrer et al., 
2004] in HCV seropositive and chronically infected HCV positive subjects were 
not able to replicate the findings of Woitas et al. although one should note that 
the study populations in these studies were different. Retrospectively, one could 
speculate that the high frequency of HHG*2/HHG*2 in the HCV positive 
individuals in Woitas study did not represent the increased susceptibility to 
HCV but rather reflected the resistance of HIV in individuals who were exposed 
to both viruses [Promrat and Liang 2003]. While associations between the 
acquisition of HCV and the genetic variability of CCR5 are limited, the role of 
CCR5 polymorphisms in response to interferon therapy is better described 
suggesting CCR5 contribution to the pathogenesis of HCV infection [Dorak et 
al., 2002; Hellier et al., 2003; Konishi et al., 2004; Promrat et al., 2003].  
 
 
5.1.8. The distribution of CCL3L1 gene copy number in IDUs 
As presented in Figure 11, the CCL3L1 gene copy number of IDUs varied from 
zero to six with the population median of two being consistent with other 
studies in Caucasian populations [Gonzalez et al., 2005; Grunhage et al., 2010; 
Shostakovich-Koretskaya et al., 2009]. In African populations, however, higher 
gene copy numbers have been demonstrated with the population average of six 
(range 0 to 11) [Gonzalez et al., 2005]. 
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Figure 11. The distribution of CCL3L1 gene copy number among 373 IDUs. The 
bars show the percentage of IDUs possessing the specific CCL3L1 copy number. 
 
 
5.1.9. CCL3L1 gene copy number and HIV serostatus 
Based on the population median in CCL3L1 gene copy number, we categorized 
subjects into two groups – those with a CCL3L1 copy number from zero to two 
(low CCL3L1 copy number) and those with greater than two (high CCL3L1 
copy number). The distribution of CCL3L1 gene copy number differed between 
HIV seropositive and HIV seronegative IDUs such that HIV seronegative IDUs 
had a greater proportion of higher gene copy number compared with HIV 
seropositives (Figure 12).  
 
 
Figure 12. The distribution of CCL3L1 gene copy number in HIV negative and 
HIV positive IDUs. Left panel bars show the frequency of specific CCL3L1 gene copy 
number and on the right panel the bars are presented as smooth lines. Blue indicates 
HIV seronegative IDUs and red indicates HIV seropositive IDUs. The p-value is 
calculated for the distribution of high and low CCL3L1 copy number. 
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In the univariate analysis, a high copy number was associated with the 
decreased odds of HIV seropositivity (OR = 0.49; 95% CI = 0.29–0.81) (Article 
1, Table 2).  
The results of the stepwise multivariate logistic regression model are 
presented in Article 1, Table 3. For the outcome of HIV seropositivity, in 
models that did not include the duration of IVDU, both HCV and HBV 
serostatus were associated with higher odds of HIV seropositivity (Article 1, 
Table 3, models 1 and 4). Conversely, in the model that did not include HCV or 
HBV serostatus, the increased duration of IVDU was associated with the 
increased odds of HIV seropositivity (Article 1, Table 3, model 5). By contrast, 
the inclusion of the duration of IVDU in the same model with HCV and HBV 
led to no associations with each of these highly correlated parameters and HIV 
seropositivity (Article 1, Table 3, models 2 and 3). However, higher CCL3L1 
copy number was associated with decreased odds of HIV seropositivity, 
independent of the duration of IVDU and HCV and HBV co-infection status 
(Article 1, Table 3, models 3–5).  
The associations between the higher than the population median of CCL3L1 
copy number and the reduced risk of acquiring HIV infection as in our study 
have been demonstrated previously in subjects exposed to HIV via sexual or 
perinatal route [Gonzalez et al., 2005; Kuhn et al., 2007; Meddows-Taylor et al., 
2006; Nakajima et al., 2007]. In addition, the slower disease progression has 
also been associated with the higher than population mean CCL3L1 copy 
numbers [Gonzalez et al., 2005; Kulkarni et al., 2008]. However, these findings 
have not been universally unidirectional. There are recent studies in which no 
associations between the CCL3L1 copy number and the susceptibility to HIV or 
the disease progression has been found in African, Indian and AA exposed or 
infected by sexual route [Bhattacharya et al., 2009; Larsen et al., 2012; Rathore 
et al., 2009; Shao et al., 2007; Urban et al., 2009]. These controversial findings 
may be explained by various population selections. It is possible that these 
associations may not be present in every population. However, the different 
origin and risk factors might influence the results.  
The debate over proper method for the detection of CCL3L1 copy number 
has been vivid. Studies that have tried to replicate the results by real-time PCR 
have failed and the accuracy of the real-time PCR assay used by Gonzalez et al., 
2005 have been questioned [Bhattacharya et al., 2009; Urban et al., 2009]. In 
addition, Field et al (2009) compared real-time PCR assay with another method 
to measure the gene copy number – paralogue ratio test (PRT) [Armour et al., 
2007; Field et al., 2009; Walker et al., 2009]. Field et al (2009) debated that in 
the case of real-time PCR (e.i. qPCR) assay rounded results were not HWE. In 
addition, the primers used in qPCR for CCL3L1 may also bind a CCL3L1 
pseudogene CCL3L2 [Gonzalez et al., 2005; Modi, 2004; Walker et al., 2009]. 
In conclusion, Field et al (2009) recommend to use PRT instead or qPCR (if 
deviation from HWE is resolved) in large well-powered samples. 
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However, these results were confronted by He et al (2009), using an 
argument that the original protocol was modified in many ways (different 
quencher, non-fixed DNA amounts in qPCR) [He et al., 2009]. He et al (2009) 
demonstrated that MGB assay underestimated the lower values of copy number 
but over estimated higher values compared to TAMRA. The PRT used by 
Fields et al (2009) quantifies two CCL3L genes (CCL3L1 and CCL3L3) but 
qPCR quantifies three (including also CCL3L2 which seems to not be a 
pseudogene [Shostakovich-Koretskaya et al., 2009], so the two assays are not 
comparable. In addition, He et al (2009) stated that HWE used by Fields et al 
(2009) would be valid if the copy number variation of individual CCL3L gene 
were both duplicated and distributed randomly on each chromosome, permitting 
accurate computation of copies per chromosome. But recent studies do not 
support that [Colobran et al., 2008; He et al., 2009; Perry et al., 2008]. 
Another study by Sudmant et al (2010) developed a method using whole-
genome shotgun sequencing data to accurately determine assay specific 
duplicated genes and the copy numbers of genes; a very high correlation 
between CCL3L1 qPCR and the whole-genome sequencing method was shown 
(r = 0.95) [Sudmant et al., 2010]. 
It is also suggested that the quality of the DNA plays a major role in order to 
determine the copy number correctly [Bhattacharya et al., 2009; Urban et al., 
2009]. We have paid much attention to the quality of the DNA; the DNA was 
extracted using the same method throughout the study, the DNA quality was 
measured by NanoDrop and stored at –80 C° (at the conditions that have been 
proven to be acceptable for DNA storage). We believe that all this reduced the 
inter-sample variability and increased reliability of the testing. At the moment 
the debate is still ongoing and more precise method is searched.  
 
 
The distribution of CCL3L1 gene copy number did not differ between HCV 
seropositive and HCV seronegative IDUs (Figure 13). 
Despite of no differences in the distribution of CCL3L1 copy number 
between HCV seropositive and seronegative IDUs (OR = 1.15; 95% CI 0.62–
2.12), we performed step-wise analyses similar to those in HIV infection. As 
demonstrated in Article 1, Table 4, the associations between HCV 
seropositivity and co-variates depend on the inclusion of co-variates. Unlike in 
HIV infection (Article 1, Table 3), the associations between CCL3L1 copy 
number and HCV seropositivity differed before and after accounting for the 
duration of IVDU. A higher CCL3L1 copy number was associated with the 
increased odds of HCV seropositivity when the duration of IVDU was included 
in the model (Article 1, Table 4, model 3) but did not associate with HCV 
serostatus when the duration of IVDU or HIV and HBV serostatus were 
excluded from the models (Article 1, Table 4, models 4 and 5). We concluded 
that CCL3L1 copy number was not associated with HCV seropositivity. 
5.1.10. CCL3L1 gene copy number and HCV serostatus 
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Figure 13. The distribution of CCL3L1 gene copy number in HCV negative and 
HCV positive IDUs. Left panel bars show the frequency of specific CCL3L1 gene copy 
number and on the right panel the bars are presented as smooth lines. Orange indicates 
HCV seronegative IDUs and green indicates HCV seropositive IDUs. The p-value is 
calculated for the distribution of high and low CCL3L1 copy number. 
 
 
To the best of our knowledge, only one study has demonstrated the protective 
effect of high CCL3L1 copy number on the susceptibility to chronic HCV 
infection in Caucasian population [Grunhage et al., 2010]. In addition, they 
demonstrated a significantly lower CCL3L1 copy number in HCV/HIV co-
infected subjects compared to healthy controls suggesting that lower copy 
number could be the risk factor for HCV/HIV co-infection.  
 
 
5.1.11. The distribution of CCL5 haplotypes and haplotype pairs  
The prevalence of IDUs who carried at least one allele of haplotype A was 
96.2%, other haplotypes were presented in less than 20% (Figure 14).  
 
Figure 14. The distribution of CCL5 haplotypes in IDUs. The bars show the 
percentage of IDUs who carry at least one specific CCL5 haplotype. 
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Accordingly, the most frequent CCL5 haplotype pair was A/A (67.4%) 
followed by A/C (11.1%), A/B (9.8%), A/D (7.9%), B/C (2.2%) and B/B, B/D, 
C/C and C/D were presented in less than one percent (Figure 15).  
As far as we are aware, the distribution of CCL5 haplotype and haplotype 
pairs (determined in this thesis) in Caucasian populations has not been studied. 
In North-Indian population, the distribution of these haplotypes was similar to 
ours [Rathore et al., 2008]. The study that included two SNPs in CCL5 showed 
that -471G/-96C (haplotype A) is most prevalent among Africans (50%), 
African-Americans (60%) and European-Americans (84%) as it is most 
prevalent in our population. Similar to us, the following haplotype was -471A/ 
-96C (present in haplotype B and C). However, -471A/-96G (haplotype D) was 
present in low frequency (1–2%) among European-Americans and African-
Americans and missing among Africans [Gonzalez et al., 2001].  
 
Figure 15. The distribution of CCL5 haplotype pairs in IDUs. 
 
 
 5.1.12. CCL5 haplotypes and HIV serostatus 
The distribution of CCL5 haplotypes in HIV seronegative and HIV seropositive 
subjects was similar suggesting that this haplotype does not influence the 
susceptibility to HIV infection (data not shown).  
 
 
5.1.13. CCL5 haplotypes and HCV serostatus 
Similar to the analyses of CCR5 haplotypes, we started with detecting the 
relationship between CCL5 haplotypes and HCV serostatus, which was 
followed by the analyses of CCR5 halpotypes and HIV/HCV co-infection, and 
ended with the inclusion of the haplotype pairs.  
13
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In HCV seropositives, the frequency of CCL5 haplotype C was higher and 
the frequency of haplotype D was lower than in the HCV seronegatives (16.8% 
vs 6.9% and 4.5% vs 20.7%, respectively; both p < 0.05). 
In a univariate logistic regression model we observed that subjects 
possessing CCL5 haplotype C had almost three times the increased odds of 
being HCV seropositive compared with those not possessing CCL5 haplotype C 
(Table 11, model 1). IDUs with CCL5 haplotype D had five times the reduced 
odds of HCV seropositivity compared with those who did not possess CCL5 
haplotype D (Table 11, model 2). Both these associations remained significant 
in a logistic regression model after the adjustment for HIV, HBV serostatus and 
the duration of IVDU (Table 11, model 1 and 2). When both haplotypes were 
included into the same model, only haplotype D remained significantly 
associated with the HCV serostatus suggesting the predominant influence of the 
CCL5 haplotype D (Table 11, model 3).  
 




Outcome: HCV seropositivity 
Unadjusted 




OR (95% CI) 
MODEL1   
CCL5 hap C
b
 2.72 (1.12–6.61) 5.19 (1.11–24.17) 
MODEL2   
CCL5 hap D
c 
0.19 (0.09–0.40) 0.10 (0.03–0.36) 
MODEL3   
CCL5 hap C
b 
2.37 (0.97–5.81) 3.79 (0.80–17.92) 
CCL5 hap D
c 
0.20 (0.09–0.43) 0.12 (0.03–0.42) 
aadjusted for HIV, HBV and the duration of IVDU.  
breference group is CCL5 non-C haplotype 
creference group is CCL5 non-D haplotype 
hap – haplotype 
 
To the best of our knowledge, this is the first study looking at associations 
between CCL5 polymorphisms or haplotypes and the susceptibility to HCV 
infection despite the well-described role of CCL5-CCR5 axis in HCV 
pathogenesis [Zeremski et al., 2007]. Most studies so far have concentrated on 
the CCL5 variability and the disease progression. For example, in Caucasian 
population CCL5 -471A (present in haplotypes B, C and D) leads to less severe 
hepatic inflammation and milder portal inflammation [Hellier et al., 2003; 
Promrat et al., 2003]. The possession of In1.1C and 3’-222C and the 
combination of -471A/In1.1C/3’222C (first two SNPs are present in haplotype 
C and D), however, are associated with the worse response to interferon-
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ribavirin therapy among patients infected with HCV genotypes 1 and 4 
[Wasmuth et al., 2004].  
 
 
5.1.14. CCL5 haplotype D and HIV/HCV co-infection status 
As seen in Figure 16, HCV monoinfected and HIV/HCV dualinfected IDUs had 
a lower frequency of haplotype D compared with double negative IDUs (HIV-
/HCV-). There were no differences between other groups. 
 
 
Figure 16. The distribution of CCL5 haplotype D among IDUs stratified by 
HIV/HCV co-infection status. 
 
 
5.1.15. CCL5 haplotype D-containing haplotype pairs and  
HCV serostatus 
Next we determined which specific haplotype D-containing haplotype pair 
contributed to the decreased odds of HCV seropositivity. The haplotype pair 
A/D was overrepresented in subjects who were seronegative for HCV compared 
with subjects who were seropositive for HCV (3.9% vs 20.7%; p < 0.001). 
IDUs who possessed A/D had the reduced odds of HCV seropositivity  
(OR = 0.16; 95% CI 0.07–0.35) compared with those who did not have this 
haplotype pair. This remained significant after the adjustment for co-variates 
(OR = 0.10; 95% CI 0.03–0.36).  
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The analyses of CCL5 haplotype pair A/D showed that IDUs who possessed 
A/D had approximately 8 times the decreased odds to be HCV monoinfected 
and HCV/HIV dualinfected (OR = 0.12: 95% CI 0.04–0.39 and OR = 0.13; 95% 
CI 0.05–0.34, respectively) compared with HIV/HCV double negative IDUs.  
 
 
5.1.16. CCR5 HHG*1, CCL5 haplotype D and HCV serostatus 
As both CCR5 HHG*1 and CCL5 haplotype D were associated with the 
decreased odds of HCV seropositivity (paragraph 5.1.4–5.1.7 and 5.1.13), we 
next conducted a multivariate logistic regression model to evaluate the 
independent effect of these haplotypes. We observed that both of these 
haplotypes were associated with the decreased odds of HCV seropositivity 
(Table 12, model 1). In the purpose of not losing the power of the analysis, we 
adjusted the model for HIV and HBV serostatus but not to the interdependent 
factor – the duration of IVDU. After the adjustment, both haplotypes remained 
significantly associated with the susceptibility to HCV (Table 12, model 1), 
suggesting that the genetic variability of both CCR5 and CCL5 may play a role 
in the susceptibility to HCV infection. However, in the interaction model the 
combination of CCR5 HHG*1 and CCL5 haplotype D was significant but after 
the adjustment for HIV and HBV serostatus the association did not remain 
significant (Table 12, model 2). 
 
Table 12. Associations between CCL5 haplotype D and CCR5 HHG*1 on HCV 
serostatus 




  OR (95% CI) OR (95% CI) 
MODEL1   
CCL5 hap D
b 
0.24 (0.11–0.54) 0.27 (0.11–0.63) 
CCR5 HHG*1
c 
0.47 (0.22–0.99) 0.43 (0.19–0.98) 
MODEL2 – interaction model   
CCL5 hap D  0.62 (0.21–1.82) 0.51 (0.17–1.57) 
CCR5 HHG*1  1.03 (0.37–2.86) 0.77 (0.27–2.21) 
CCL5 hap D x CCR5 HHG*1 0.03 (0.00–0.38) 0.08 (0.01–1.03) 
aadjusted for HIV and HBV status.  
breference group is CCL5 non-hap D 
creference group is CCR5 non-hap HHG*1 
hap – haplotype; HH – human haplotype 
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5.2. The effect of TLR3 rs3775291  
on the susceptibility to HIV 
To evaluate the relationship between TLR3 rs3775291 polymorphism and HIV 
serostatus we recruited 345 IDUs in 2011 as described above (Table 4).  
 
 
5.2.1. The population characteristics of TLR3 study  
The detailed characteristics of study populations are presented in Article 3, 
Table 1. Briefly, similar to other population in this thesis, half of the IDUs were 




5.2.2. The distribution of TLR3 rs3775291  
The T allele frequency of TLR3 rs3775291 was 36% among HIV seronegative 
IDUs (48% in HESNs, 34% in non-HESNs and 35% in unexposed IDUs), 31% 
among HIV seropositive IDUs and 34% among blood donors. The TLR3 
rs3775291 was in the Hardy-Weinberg equilibrium in all the groups. The 
frequencies of TLR3 rs3775291 genotypes in HESNs, non-HESNs and blood 
donors are presented in Article 3, Table 2. Our results of T allele frequency 
blood donors are similar to prior studies on Caucasian populations [Kindberg et 
al., 2011; Sironi et al., 2012]. The frequency of T allele among HESNs was 
higher in our study compared to Sironi et al (2012) but it was not significant.  
 
 
5.2.3. TLR3 rs3775291 and HIV serostatus 
The number of persons who possessed T allele was significantly greater among 
HESNs compared to blood donors (80% vs 55%; p = 0.037) and HESNs 
compared to HIV seropositive IDUs (80% vs 53%; p = 0.031) (Figure 17, right 
panel). The possession T allele did not differ between non-HESNs and other 
groups. In addition, the distribution of TLR3 rs3775291 genotypes did not differ 
between the study groups and was similar to other Caucasian populations 
[Kindberg et al., 2011; Sironi et al., 2012].  
The control populations in the previous study by Sironi et al (2012) and in 
our study were similar in terms of T allele frequency. However, we found the T 
allele on a higher frequency in HESNs than Sironi et al (2009) but a different 
population size and the extent of exposure (20 IDU HESNs vs 83 sexually and 
102 IDU exposed HESNs) in these two studies have to be noted. In addition, the 
definition of HESN differed between our and their study. We defined HESNs 
based on the frequency of receptive sharing during six last months. Sironi et al 
(2009) included persons who shared needles more than 3 months (IDU HESNs) 
and persons who had unprotected sexual episodes more than 4 years (more than 





Figure 17. The distribution of TLR3 rs3775291 genotypes (on the left) and T allele 
frequency (on the right) among the HIV positive (HIV+), non-heavily exposed HIV 
seronegative subjects (non-HESNs), heavily exposed HIV seronegative subjects 
(HESNs) and blood donors. On the left: blue indicates persons possessing CC 
genotype, red CT persons possessing genotype and green persons possessing TT 
genotype. On the right: blue indicates persons who do not possess T allele and red 
indicates persons who possess T allele.  
 
 
In the univariate analysis, the possession of TLR3 T allele was associated with 
the decreased odds of HIV seropositivity in HESNs (OR = 0.29; 95% CI 0.09–
0.90) (Article 3, Table 3). In the multivariate analysis, the possession of TLR3 
T allele and HCV seropositivity both were significantly associated with HIV 
seropositivity (Article 3, Table 3) indicating the independent effect of these two 
variables. Our results of TLR3 T allele being associated with the decreased odds 
of HIV infection confirm those of Sironi et al (2012) demonstrating that TLR3 
rs3775291 T allele plays a role in the resistance to HIV infection in HESNs.  
 
 
 5.2.4.  TLR3 rs3775291 and HCV serostatus 
As seen in Table 13, there were no differences in the distribution of TLR3 
rs3775291 T allele between HCV seropositives and seronegatives (including 
highly exposed) suggesting that this genotype is not associated with the 
susceptibility to HCV infection.  
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Table 13. The distribution of TLR3 rs3775291 T allele frequency between IDUs 
groups stratified by HCV and HBV infection and compared to blood donors and 
HCV or HBV positive IDUs 
Populations 
TLR3 rs3775291 





1. HCV- IDUs vs HCV+ IDUs  62% (39) vs 56% (306) 0.50 
2. HCV- IDUs vs blood donors 62% (39) vs 55% (497) 0.50 
3. HCV- non-highly exposed IDUs
a
 vs HCV+ 
IDUs 
75% (8) vs 56% (306) 0.47 
4. HCV- non-highly exposed IDUs
a
 vs blood 
donors 
75% (8) vs 55% (497) 0.31 
5. HCV- highly exposed IDUs
b
 vs HCV+ IDUs 100% (4) vs 56% (306) 0.13 
6. HCV- highly exposed IDUs
b
 vs blood donors 100% (4) vs 55% (497) 0.13 
apersons who reported the use of previously used syringes (receptive sharing) less than once a 
month 
bpersons who reported the use of previously used syringes (receptive sharing) at least once a 
month 
- seronegative; + seropositive  
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6. GENERAL DISCUSSION 
The susceptibility to blood borne viruses (e.g. HIV and HCV) is influenced by 
several factors of which the leading role is taken by risk behaviour such as 
needle sharing among IDUs or unprotected sex in general population. Among 
others, host genetic factors have shown to have an impact to the susceptibility to 
complex diseases as well as infections diseases. The host genetic factors and 
population characteristics are likely interrelated. It is known that the ethnicity is 
a crucial factor in host genetics studies as the genetic background differs 
between populations (e.g. genetic variation in Caucasians vs. Africans).  
 
 
6.1. The importance of studies related to HIV and  
HCV in IDUs  
The majority of previous research on HIV infection has been conducted in 
sexually (homo or hetero) or perinatally infected subjects (see chapter 2.7.3.2). 
Most likely because it is one of the leading transmission routes of HIV and 
compared to other risk groups these subjects are easier to reach and monitor. 
Thus, in these populations the relationships between the genetic host factors and 
the susceptibility and progression of HIV infection have been relatively well 
described – several genes have been identified. However, very limited data is 
available on IDUs, the population that is different from sexually transmitted 
population for several reasons. Firstly, due to sharing contaminated needles the 
risk of infection with blood borne viruses is much higher than by any other 
route. Secondly, bearing in mind that in the case of intravenous transmission the 
viruses do not pass the mucosal barrier, it is possible that host genetic factors in 
this transmission route have a different role than in other routes [Shaw and 
Hunter, 2012]. Furthermore, IDUs who despite the very high risk remain 
uninfected form an interesting and valuable group for studies on factors that 
influence the susceptibility to HIV. Thirdly, most of the IDU-epidemics 
(including the Estonian one) consist of monophyletic viral population, which 
could be the results of the lack of mucosal barrier and fast spread of one viral 
strain instead of multiple strains [Avi, 2011]. This unique situation provided us 
an opportunity to minimise the potential influence of viral heterogeneity 
commonly seen in sexually transmitted epidemics. Fourthly, the vast majority 
of subjects in the IDU studies, including ours, are also infected with HCV and 
in lesser extent with HBV allowing to evaluate the effect of the host genetic 
factors in the context of co-infection. 
All abovementioned population advantages were seen in our study on 
Estonian IDUs. Vast majority of subjects were young (median age 26–30 
years), all were Caucasian and majority were males (approximately 80%). The 
rate of HIV infection was high (50–56%), more than three quarters (76–89%) 
had HCV infection and nearly 40% HIV/HCV co-infection. The monophyletic 
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viral population consisting predominantly of CRF06_cpx viruses has been 
repeatedly described in Estonia [Avi et al., 2009; Avi et al., 2010; Avi et al., 
2011] and was undoubtedly another advantage of our study. Taken together, we 
have studied a homogenous population where the influence of environmental, 
viral and risk behaviour factors was similar.  
 
 
6.2. The pros and cons of study design 
Ideally, in order to evaluate the influence of host genetic factors on the 
susceptibility to blood borne infections in IDUs one would aim to conduct a 
long-term prospective study. First, to observe the susceptibility to the virus and 
second, to detect the risk behaviour in more detail over the course of time. A 
study of such population will be logistically very difficult if not impossible. 
Thus, we have decided to conduct cross-sectional studies but appreciate that this 
design could also have problems. In the case of cross-sectional study, the 
causality cannot be determined, the population size should be relatively large 
(e.g. in the case of rare outcomes and factors) and in the secondary analysis 
there is no control over the choice or the methods of data collection. On the 
other hand, a cross-sectional study will also have several advantages because it 
enables to identify the new associations, which could be evaluated in more 
detail and rigorously in the cohort studies in the future. Following the 
advantages of cross-sectional study, design should be noted: (i) studies are 
relatively easy to conduct in a short period of time; (ii) they are less resource 
consuming; and (iii) there is a higher chance to complete the data collection 
than in prospective studies. Bearing the abovementioned in mind, we have 
chosen the cross-sectional study design for four reasons. First, as known IDUs 
population is hard to recruit and even more complicated to follow prospectively. 
Second, the data collection had to be manageable. Third, the study budget was 
limited. Finally, we looked at the genetic factors that had not been described in 
IDU population and because of that the cross-sectional study design met our 
needs to evaluate the associations at the beginning.  
 
 
6.3. The role of CCR5-CCL5 variability in HCV infection 
Although several host genetic factors have been evaluated in the context of HIV 
infection the genes encoding CCR5 and its ligands are by far the most 
commonly targeted. This is not surprising as the homozygocity of 32 bp 
deletion in CCR5 is the only genetic polymorphism that offers complete 
protection against R5-tropic HIV infection [Samson et al., 1996]. CCR5 and its 
ligand CCL5 genes have also been studied in HCV infection, especially looking 
at the response to therapy. Mostly the different SNPs in these genes have been 
evaluated and shown that CCR5 polymorphisms have an influence on the HCV 
disease outcome (see chapter 2.8.3.2).  
15
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Until now, less attention has been paid to CCR5 haplotypes. To the best of 
our knowledge, for the first time we have shown that persons with CCR5 
HHG*1, the haplotype upon which CCR5-Δ32-containing HHG*2 arose, had 
the decreased odds of HCV seropositivity independent of other factors (HCV, 
HBV serostatus and duration of IVDU) associated with HCV susceptibility. In 
addition, we saw that CCL5 variability was associated with HCV susceptibility 
so that the CCL5 haplotype D (-471A/-96G/In1.1C) had a protective effect 
against HCV seropositivity. So far, only HHG*2/HHG*2 (homozygocity of 
CCR5-∆32) had been associated with an increased risk of HCV infection, but 
this finding may reflect the resistance to HIV rather than the increased 
susceptibility to HCV infection [Woitas et al., 2002]. We did not find 
associations between the CCR5-Δ32 homozygocity and the susceptibility to 
HCV.  
Although the mechanism behind these associations is unknown, the reasons 
why CCR5 and CCL5 are important in HCV infection may lie in the overall 
immune response and the role of CCR5-CCL5 in HCV pathogenesis. First, the 
CCR5 is one of the chemokine receptors that is responsible for recruiting a 
variety of immune cells (e.g. monocytes, DCs, NK) to the sites of inflammation, 
and induces Th1 response in order to control infection and eliminate antigens. 
Together with that, the interaction between CCR5 and CCL5 has an effect on T 
cell activation [Dairaghi et al., 1998; Manes et al., 1999; Nguyen and Taub, 
2002; Xiao et al., 1999]. Second, specifically in HCV infection, the lack of Th1 
response leads to the development of chronic HCV infection in which the 
CCR5-CCL5 axis could play a crucial role [Lechner et al., 2000a; Zeremski et 
al., 2007; Woitas et al., 1997]. In addition, HCV itself interacts directly with 
CCR5 and CCL5 resulting in the decreased chemotactic responsiveness to 
CCL5 in CD4+ and CD8+ cells and keeps CCR5 expressing HCV-specific T 
cells away from the infection site in order to prevent viral clearance [Lechner et 
al., 2000b; Losana et al., 2002; Nattermann et al., 2004; Solari et al., 1997; Soo 
et al., 2002; Thimme et al., 2001]. This all suggest that CCR5 and CCL5 play 
an important role in the immune responses and through that the haplotypes of 
CCR5 and its ligands’ genes might influence HCV infection. 
Thus, one potential mechanism behind our findings might be the influence of 
CCR5 and CCL5 haplotypes on their expression and by that modulating the Th1 
response in order to eliminate the viruses. Despite the fact that some SNPs and 
group of haplotypes have been shown to influence the receptor expression (e.g. 
minor alleles in CCL5 promoter SNPs enhance CCL5 production and CCR5 
HHA-HHE have higher transcription activity), the mechanism how CCR5 
HHG*1 and CCL5 haplotype D affect their expression is largely unknown [An 
et al., 2002; Lin et al., 1999; McDermott et al., 1998; Mummidi et al., 2000]. 
On the other hand, the associations determined by us might not be mediated 
directly through CCR5 and CCL5.  
In addition to the associations between CCR5 HHG*1 and HCV, we 
observed that CCR5 HHF*2 had a protective effect against HIV but the 
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association was weak and lost its significance after the adjustment for co-
variates (HCV, HBV serostatus and the duration of IVDU). Thus, we could not 
demonstrate that CCR5 haplotypes had an independent effect on HIV 
susceptibility in IDUs population. 
 
 
6.4. The role of CCL3L1 copy number in HIV infection 
Beside SNPs, there is also a gene copy number variation, which is a rarer 
polymorphism than SNPs but covers larger genomic regions. In recent years, 
there has been a great attention on the CCL3L1 gene copy number in HIV 
infection research. It is due to CCL3L1 being a ligand for CCR5 and the most 
potent inhibitor of R5-tropic HIV strains [Aquaro et al., 2001; Menten et al., 
1999]. We demonstrated that a higher than population median CCL3L1 copy 
number had a protective effect against HIV susceptibility independent from 
other factors that strongly influence HIV acquisition such as the duration of 
intravenous drug use. This is in concordance with the previous findings in other 
risk groups infected with HIV via sexual route or by blood products 
(hemophiliacs) [Gonzalez et al., 2005; Nakajima et al., 2007].  
The potential mechanism behind the protection of higher CCL3L1 copy 
number against HIV infection could be viral entry-dependent. The higher 
CCL3L1 copy number is associated with the increased mRNA and 
CCL3/CCL3L1 protein levels and a lower percentage of CD4+CCR5+ cells 
[Gonzalez et al., 2005; Meddows-Taylor et al., 2006; Townson et al., 2002; 
Urban et al., 2009]. This indicates that when there is a high level of CCL3L1 
then a competition between CCL3L1 and HIV occurs in order to bind with 
CCR5. In addition, higher amount of CCL3L1 could down-regulate CCR5 
expression on the cell surface and by that directly influence the viral entry into 
the cells (ref). However, a recent study showed that CCL3L1 mRNA did not 
correlate with gene copy number while the ratio of CCL3L1:CCL3 correlated 
significantly [Carpenter et al., 2012]. Carpenter et al suggested that the majority 
of CCL3L protein is CCL3, but at the moment there is no specific antibody to 
prove that.  
On the other hand, the viral entry-independent mechanism could also 
potentially explain the associations between gene copy numbers and the 
susceptibility to HIV infection. For example, the entry-independent might 
include T cell regeneration and activation induced cell death, the formation of 
immunological synapse and cell-mediated immunity (CMI) [Castellino et al., 
2006; Lillard et al., 2003; Molon et al., 2005]. Dolan et al showed that certain 
CCL3L1-CCR5 genotypes (non-detrimental CCR5 haplotypes and CCL3L1 
copy number higher than population median) alter CMI (measured as delayed-
type hypersensitivity responses) in both healthy and HIV infected subjects and 
these genotypes are similar to those that influence the risk of HIV transmission 
and the disease progression. Still, analyses demonstrated that the CCL3L1-
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CCR5 genotypes influence the HIV course independently of their effects on 
viral load and CMI. Thus, Dolan et al indicated that the effect of CCL3L1-
CCR5 genotype on HIV disease course includes the viral entry-independent 
processes (such as CMI) and suggested that their effect might be even greater 
than entry-dependent processes. Based on these results, it could be speculated 
that similar processes are affecting also the viral transmission but how and in 
which extent is still to be explored.  
 
 
6.5. The detection of gene copy number 
Still, a vivid debate behind the controversial results of the associations between 
CCL3L1 copy number and HIV infection is ongoing and the accuracy of qPCR 
to measure CCL3L1 copy numbers has been raised [Bhattacharya et al., 2009; 
Field et al., 2009; Shrestha et al., 2010a; Urban et al., 2009]. Actually, this 
problem is not specific only to CCL3L1 but also other genes with the copy 
number variation. The gene copy number variation is a form of structural 
variation in the genome where the duplication or deletion of DNA segments 
occurs. Because of the varying length of DNA segments (1–400 kb) and a high 
level of sequence identity (>90%) it is difficult to measure the copy number 
compared with the detection of SNPs.  
Many different assays have been developed to determine a copy number 
variation starting with fluorescence in situ hybridization and ending with next-
generation sequencing (NGS). Today, several NGS-based methods have been 
developed [Duan et al., 2013]. These methods vary by the NGS reads (single-
end or pair-end), software and algorithms. Although NGS technology is a 
powerful tool, it still produces short sequences that complicate the mapping 
processes. In addition, the results of Duan et al (2013) showed that more 
efficient software and improved algorithms are needed. They compared six 
different NGS-methods and produced the recommendations for choosing the 
method based on the researchers priorities. However, all NGS-methods are 
developed using full genome data, thus, today’s NGS-technology is still rather 
resource consuming especially in the association studies where hundreds of 
subjects should be evaluated. On the other hand, the locus-specific NGS 
methods could be developed but in this case the bottleneck would be the 
amplification processes. Bearing in mind the features of copy number variation, 
it is hard to design appropriate primers to amplify the right regions including all 
copies. Nevertheless, the progression of technology and accelerated 
development of software, the NGS-based methods for the copy number 
variation will soon be used widely in the detection of gene copy numbers.   
The determination of CCL3L1 copy number was carried out by qPCR the 
method that was available at the moment we conducted our experiments. We 
have not measured the copy number with other methods like PRT or NGS-
based methods. Still, Sudmant et al (2010) have shown a high correlation 
65 
between CCL3L1 qPCR and whole-genome shotgun sequencing data to 
accurately determine assay specific duplicated genes and the copy numbers of 
genes (r = 0.95). This suggests that the qPCR results and findings of Gonzalez 
et al and ours in this study on CCL3L1 copy number are correct allowing to 
drawn reliable conclusions. 
 
 
6.6. Study limitations 
Some limitations of the current thesis should be acknowledged. First, the 
duration of IVDU, a crucial factor in the acquisition of HIV and HCV infection 
was available only for two thirds of the CCL3L1, CCR5 and CCL5 study 
population missing from IDUs from prison due to a technical error. However, 
populations from prison and the syringe exchange programme were similar in 
terms of demographic and risk behaviours, and in the multivariate analysis they 
did not influence the principle findings (Article 2; Table 4). Thus, we believe 
that the duration of IVDU is similar between the populations, and associations 
in one population can be extrapolated to the whole population. Another 
population bias was that all IDUs recruited from prisons were HIV positive and 
the rate of HIV/HCV co-infection was higher than in IDUs from the syringe 
exchange programmes (Results; Table 6). This may be due to the fact that HIV 
negative populations cannot be recruited from prisons. Nevertheless, we believe 
that despite these small discrepancies, these two populations are similar in terms 
of demographics and risk behaviour. Therefore, the patients from two sources 
likely do not influence the associations between CCR5 and its ligands CCL3L1 
and CCL5 genetic variability and HIV/HCV serostatus. In addition, due to the 
high rate of HIV/HCV co-infection the number of HCV monoinfected or 
uninfected subjects was relatively small and accordingly the power of several 
analyses was thus diminished. Finally, the HIV negative group was relatively 
small in all studies, especially HESNs group in TLR3 study but it has to be 
noted that this group among IDUs is very rare because most of the highly 
exposed IDUs become infected with HIV suggesting that factors that protect a 
person from HIV infection are very rare. In spite of that, the associations 
between the evaluated host genetic factors and HIV and HCV infections 
remained significant in both the uni- and multivariant analysis. Regardless of 
these limitations, we believe that the results presented here adequately describe 
the role of host genetic factors in the acquisition of HIV and HCV infection. 
 
 
6.7. Future research 
The currents thesis revealed associations between host genetic polymorphisms 
and HIV and HCV acquisition. Still, there are several questions that we were 
not able to address using this study design and methods. Firstly, how the CCR5 
haplotypes and especially haplotype pairs influence the expression of CCR5 on 
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different cell types (CD4+, CD8+, naïve and memory T cells etc.). So far the 
studies have evaluated only single SNPs or the cluster of haplotypes. It will be 
most interesting to find how CCR5 haplotype pairs are related to the receptor 
expression, especially because the expression of CCR5 may be impacted by the 
partner allele. Secondly, how the opioids influence the expression of CCR5 and 
how are they influenced by CCR5 haplotypes and haplotype pairs. There are 
suggestions that opioids (e.g. cocaine), widely used by Estonian IDUs [Uuskula 
et al., 2010], increase the expression of CCR5. How this process is influenced 
by different CCR5 haplotypes is largely unknown.  
Another issue that was not evaluated in the current study but is crucial is the 
relationship between host genetic factors and HIV disease progression in IDU 
population. As discussed above, IDUs are a unique population and there is a 
lack of knowledge about many processes in the disease course. However, it is a 
challenge to recruit this population especially into the prospective studies. Since 
2009, an Estonian HIV database has been established containing at present data 
on more than 3000 HIV positive patients from different risk groups (including 
IDUs). In addition, this database contains biosamples from HIV positive 
subjects. This will enable evaluating the effect of host and viral genetic as well 
as immunological factors on HIV disease progression in IDUs. In addition, 
finding out the relationship between antiretroviral regimens and host genetic 
factors would give a practical value allowing physicians to select the most 













 In Caucasian IDUs, similar to other risk groups of blood-borne infections 
and ethnic groups, the median CCL3L1 gene copy number affects the 
susceptibility to HIV infection such that IDUs possessing a higher gene copy 
number than the population median have significantly decreased odds of 
HIV positivity to those with lower than population median copy number. 
This suggests that the effect of CCL3L1 copy number is independent of the 
route of transmission. The potential mechanism behind this association 
might be that the higher CCL3L1 expression blocks the binding of HIV to 
the receptor and/or diminishes the expression of CCR5 onto the cell surface. 
In addition, the entry-independent pathway might also contribute to this 
process. There is no association between CCL3L1 copy number and the 
susceptibility to HCV infections. 
2.
 HCV seropositivity depends on CCR5 haplotypes. More specifically, 
persons with CCR5 HHG*1 or haplotype pair HHE/HHG*1 are more likely 
protected from HCV infection compared to those not having this haplotype/ 
haplotype pair. These data suggest that CCR5 haplotypes/haplotype pairs, in 
addition to being involved in the responses to the therapy in chronic HCV 
infection, are also associated with the susceptibility to the HCV infection. 
The CCR5 haplotypes have no independent effect on the susceptibility to 
HIV infection in IDUs.
 
1.
3. The CCL5 haplotype D (-471A/-96G/In1.1C) is protective against HCV, 
highlighting the role of CCL5 variability in CCL5-CCR5 axis on the 
susceptibility to HCV in IDUs. However, in contrast to previous studies 
describing the associations between the CCL5 variability and the 
susceptibility to HIV in the multiethnic sexually exposed or infected, we 
were not able to demonstrate the same in IDUs suggesting that this effect is 
not universal and may not exist in the case of intravenous transmission. 
4. TLR3 rs3775291 influences HIV seropositivity in HESNs such that T allele 
gives protection against HIV infection. The protective effect of TLR3 T 
allele suggests the immunologically mediated protection from HIV infection 
through TLR3 by recognising the virus. There are no associations between 





8. SUMMARY IN ESTONIAN 
Inimese geneetiliste faktorite mõju HIV-i ja C-hepatiidi viirusesse 
nakatumisele süstivate narkomaanide hulgas 
Süstitavate narkootikumide kasutamine on maailmas toonud kaasa vere teel 
levivate viiruste, nagu inimese immuunpuudulikkuse viirus (HIV) ja C-hepatiidi 
viirus (HCV), kiire leviku. Praeguseks elab maailmas umbes 35 miljonit 
inimest, kes on nakatunud HIV-i, ja 130 miljonit, kes on nakatunud HCV-sse. 
Kui HCV puhul umbes 20% inimestest suudab ise viirusest vabaneda, siis HIV 
infektsiooni ei suuda inimese immuunsüsteem elimineerida.  
Inimesi, kes ei nakatu HIV-i isegi peale mitmeid ekspositsioone viirusega, 
nimetatakse kõrgelt eksponeeritud HIV seronegatiivseteks isikuteks (KESN). 
Selliseid isikuid võib leida (i) kontamineeritud süstlaid jagavate süstivate 
narkomaanide (SN) seast; (ii) inimeste seast, kes said epideemia algusaastatel 
HIV-positiivse vere ülekandeid; (iii) HIV-positiivsetel emadelt sündinud laste 
seast; ja (iv) HIV-positiivsete isikute seksuaalpartnerite seast. Kuna siiani pole 
täpselt teada, mis põhjustel need inimesed ei nakatu, pakub see uurijatele suurt 
huvi. 
HIV-i nakatumist mõjutavad paljud faktorid, nagu näiteks nakatumistee, 
nakataja viirushulk, teised kaasnevad seksuaalsel teel levivad haigused ja 
inimese immunoloogilised faktorid. Lisaks sellele mõjutavad nakatumist ka 
inimese geneetilised faktorid, millest tuntuim on 32-aluspaariline deletsioon 
HIV ko-retseptorit CCR5-te kodeerivas geenis. Nimetatud mutatsiooni homo-
sügootsus annab resistentsuse HIV R5-troopsetele viirustele. Samuti on tuvas-
tatud erinevates geenides mitmeid polümorfisme, mis mõjutavad HIV-i 
nakatumist. Siiani on inimese geneetiliste faktorite uuringud läbi viidud 
peamiselt populatsioonides, kus nakatumine on toimunud kas seksuaalsel teel 
või ülekandel emalt lapsele. Vähe on teada geneetiliste faktorite mõju kohta SN-
de seas, populatsioonis, mis on valdav endise Nõukogude Liidu riikide HIV 
epideemiates, kaasa arvatud Eestis.  
Eestis sai HIV-1 epideemia alguse 2000. aastal, kui Euroopas haruldane 
HIV-1 rekombinantne vorm CRF06_cpx sisenes SN-de populatsiooni. 
Epideemiat iseloomustas HIV-1 kiire levik peamiselt noorte meessoost SN-de 
seas ja kõrge HCV levimus. Kuna tegemist on homogeense populatsiooniga, 
siis annab see võimaluse kirjeldada inimese geneetiliste faktorite mõju HIV-i ja 
HCV-sse süstimise teel nakatumisele.   
 
Uurimistöö eesmärgid 
Töö üldine eesmärk oli kirjeldada inimese immuunsüsteemi kodeerivate geenide 





Uuringu alaeesmärgid olid: 
1. Kirjeldada CCL3L1 geeni koopiaarvu ning HIV-i, HCV-sse ja/või HBV-sse 
nakatumise vahelisi seoseid SN-de seas.  
2. Kirjeldada CCR5 haplotüüpide/haplotüübi paaride ning HIV-i ja/või  
HCV-sse nakatumise vahelisi seoseid SN-de seas.  
3. Kirjeldada CCL5 haplotüüpide/haplotüübi paaride ning HIV-i ja/või  
HCV-sse nakatumise vahelisi seoseid SN-de seas. 
4. Kirjeldada TLR3 polümorfismi ning HIV-i ja/või HCV-sse nakatumise 
vahelisi seoseid SN-de seas. 
 
 
Uuritavad ja metoodika 
Uuring viidi läbi neljas osas: 
1. CCL3L1 uuring, mis määras CCL3L1 geeni koopia arvu ja selle seoseid 
HIV-i ja/või HCV-sse ja HBV-sse nakatumisega. Uuritavateks olid 374 SN-
i, kes olid kaasatud süstlavahetuspunktidest ja Eesti vanglatest 2006–2007 
aastal. Uuritavad olid valdavalt noored mehed (keskmine vanus 26 aastat, 
mehi 80%).  
2. CCR5 uuring, mis kirjeldas CCR5 haplotüüpe ja haplotüübi paare ning 
nende seoseid HIV-i ja/või HCV-sse nakatumisega. Uuritav valim koosnes 
valdavalt eeltoodud SN-dest. Lisaks kaasati uuringusse 500 HIV-, HCV- ja 
HBV-negatiivset veredoonorit.  
3. CCL5 uuring, mis keskendus CCL5 haplotüüpidele ja haplotüübi paaridele 
ning nende seostele HIV-i ja/või HCV-sse ja HBV-sse nakatumisega. 
Uuritavateks olid valdavalt eelmainitud SN-d. 
4. TLR3 uuring, mis määras TLR3 rs3775291 polümorfismi ja selle seoseid 
HIV-i ja/või HCV-sse ja HBV-sse nakatumisega. Uuritavateks olid 2011. 
aastal süstlavahetuspunktist kaasatud 345 SN-i ning 497 eelnevalt kirjel-
datud veredoonorit. 
 
Uuring viidi läbi TÜ Tervishoiu Instituudi, Tervise Arengu Instituudi, Tartu 
Vangla ja TÜ Mikrobioloogia Instituudi koostööna.  
Kõikides uuringutes eraldati isikute verest inimese genoomne DNA. 
CCL3L1 koopia arv määrati Real-Time PCR-ga nagu kirjeldatud Gonzalez et al 
(2005) poolt. CCR5, CCL5 ja TLR3 polümorfismid määrati kasutades Real-
Time PCR Allelic Disclimination Assay’d või RLFP-PCR-i. CCR5 haplotüüpide 
aluseks oli Gonzalez et al (1999) poolt kasutuses olev evolutsioonipõhine 
klassifikatsioon. CCL3L1 koopia arvu ja TLR3 polümorfismi määramine viidi 
läbi TÜ Mikrobioloogia Instituudis ning CCR5 ja CCL5 polümorfismide 
määramine professor Sunil K. Ahuja laboris Texase Ülikoolis San Antonios 
USAs. 
Statistilises analüüsis kasutati haplotüüpide/haplotüübi paaride jaotuse 
võrdlemisel Fisheri täpset testi ja hii-ruut testi ning mudelite puhul ühe- ja 
mitmemõõtelist logistilist regressiooni. 
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Peamised tulemused ja arutelu 
Ootuspäraselt nägime, et SN-de1, kes olid HCV- ja HBV-positiivsed, olid 
suuremad šansid olla ka HIV-positiivsed, ning SN-del, kes olid HIV- ja HBV-
positiivsed, olid suuremad šansid olla HCV-positiivsed. Samuti tõstis 
pikaajaline süstitavate narkootikumide kasutamine HIV-i ja HCV-sse naka-
tumise šansse, samas ei mõjutanud SN-de vanus ega sugu HIV-i ja HCV-sse 
nakatumist. Neid faktoreid, mis mõjutasid HIV-i ja HCV-sse nakatumist, 
kasutati mudelites kaasuvate faktoritena (HCV, HBV serostaatus, süstitavate 
narkootikumide kasutamise kestvus).  
Kõikide uuringus määratud geenide polümorfismid ja nendest tulenevate 
haplotüüpide esinemissagedus sarnanes varem kirjeldatud europiidsesse rassi 
kuuluvate populatsioonide andmetega. CCR5 haplotüüpidest oli sagedaseim 
HHE (56% doonoritel ja 55% SN-l), CCL5 haplotüüpidest A (96% SN-l), 
CCL3L1 koopia arvu populatsiooni mediaan oli 2 ja TLR3 rs3775291 T-alleeli 
sagedus 34%.  
Ainuke CCR5 haplotüüp, mille sagedus oli oluliselt erinev HIV-negatiivsete 
ja HIV-positiivsete SN-de vahel, oli HHF*2 (23,5% vs 15,0%; p<0,05). SN-del, 
kes omasid HHF*2, oli peaaegu 2 korda väiksemad šansid olla HIV-positiivne 
kui SN-del, kellel see haplotüüp puudus (OR=0,57; 95% CI 0,34–0,98, 
p=0,041). Kuid pärast mudeli kohandamist kaasuvatele faktoritele (HCV ja 
HBV staatus, süstitavate narkootikumide kasutusaeg) ei olnud seos enam 
oluline. Siiski, varasemates uuringutes on näidatud HHF*2 kaitsvat rolli HIV-i 
nakatumisel ülekandel emalt lapsele. Võrreldes CCR5 haplotüüpide jaotuvust 
HCV-positiivsete ja -negatiivsete SN-de vahel, selgus, et HHG*1 oli sagedasem 
HCV-negatiivsete seas kui -positiivsete seas (20,7% vs. 7,5%; p<0,001). 
Ühemõõtmeline logistiline regressioonanalüüs näitas, et SN-del, kes omasid 
HHG*1, olid väiksemad šansid olla HCV-positiivne (OR = 0,37; 95% CI = 
0,16–0,82), mis jäi oluliseks ka peale kohandamist kaasuvatele faktoritele (OR 
= 0,07; 95% CI 0,03–0,20). Analüüsidest selgus, et HHG*1 sisaldav haplotüübi 
paar HHE/HHG*1 on sarnaselt HHG*1 seotud HCV-sse nakatumisega. CCR5 
haplotüüpidele sarnane analüüs viidi läbi CCL5 haplotüüpide mõju hindamisel. 
Selle tulemusel selgus, et CCL5 haplotüüp D olemasolu vähendas šansse olla 
HCV-positiivne (OR = 0,20; 95% CI 0,09–0,43), mis jäi oluliseks ka peale 
kohandamist kaasuvatele faktoritele (OR = 0,12; 95% CI 0,03–0,42). Meie 
teada on see esimene uuring, mis mainitud seoseid näitas. Varasemalt on Woitas 
et al (2005) HCV-sse nakatumist seostanud CCR5-32 homosügootsusega, 
kuid hilisemad uuringud ei ole sellist seost näidanud, ja arvatakse, et Woitas et 
al tulemus peegeldas resistentsust pigem HIV-le kui HCV-le. Meie tulemused 
viitavad nii CCR5 kui CCL5 geneetilise mitmekesisuse olulisusele HCV 
infektsioonis, aga ei ole teada, mis mehhanismi läbi.  
CCL3L1 koopia arv oli suurem HIV-negatiivsete SN-de seas võrreldes HIV-
positiivsetega. Ühemõõtmeline logistiline regressioonanalüüs näitas, et SN-del, 
kellel oli CCL3L1 koopia arv kõrgem kui populatsiooni mediaan, olid suuremad 
šansid olla HIV-negatiivsed (OR = 0,49; 95% CI 0,29–0,81). Antud seos jäi 
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oluliseks ka peale mudeli kohandamist kaasuvatele faktoritele. Sellist seost on 
varem kirjeldatud isikutel, kes on eksponeeritud seksuaalselt või perinataalselt. 
Samas nägime, et CCL3L1 koopia arv ei ole seotud HCV staatusega.  
TLR3 rs3775291 vähemalt ühe T-alleeli esinemine erines KESN-de, HIV-
positiivsete ja doonorite vahel (vastavalt 80% vs 53% vs 55%; kõigil p<0,05). 
Ühemõõtmeline logistiline regressioonanalüüs näitas, et KESN-idel, kellel oli 
vähemalt üks T-alleel, olid väiksemad šansid HIV-i nakatuda kui KESN-idel, 
kellel seda alleeli ei olnud (OR = 0,29; 95% CI 0,09–0,90). Seos jäi oluliseks ka 
peale kaasuvatele faktoritele kohandamist. Meie tulemused kinnitasid varase-




1. CCL3L1 geeni koopia arv mõjutab HIV-i nakatumist SN-de seas. Sarnaselt 
teiste erinevat päritolu riskirühmadega, on populatsiooni mediaanist suurem 
CCL3L1 koopia arv seotud HIV infektsiooni eest kaitsva efektiga, viidates, 
et CCL3L1 mõju ei sõltu nakatumisviisist. Võimalik mehhanism võib olla 
seotud kõrgema CCL3L1 ekpressioonitasemega, mille tõttu CCL3L1 
blokeerib HIV-i seondumise tema ko-retseptori CCR5-ga ja/või vähendab 
CCR5 ekspressiooni raku pinnal. CCL3L1 koopia arv ei ole seotud HCV-sse 
nakatumisega. 
2. CCR5 haplotüübid mõjutavad HCV seropositiivsust, nii et CCR5 haplotüüpi 
HHG*1 või haplotüübi paari HHE/HHG*1 omavatel isikutel on väiksemad 
šansid olla HCV seropositiivsed võrreldes isikutega, kes neid ei oma. Need 
tulemused viitavad, et lisaks CCR5 haplotüüpide rollile kroonilise HCV 
ravivastuses, on need olulised ka nakatumisel. CCR5 haplotüübid ei ole 
seotud HIV nakatumisega SN-de seas. 
3. CCL5 haplotüüp D (-471A/-96G/In1.1C) omab HCV-sse nakatumisel 
kaitsvat efekti. See tõstab esile CCL5 geneetilise mitmekesisuse olulisuse 
HCV-sse nakatumise kontekstis. Samas CCL5 haplotüübid ei ole seotud 
HIV-i nakatumisega nagu on eelnevalt demonstreeritud seksuaalsel teel 
eksponeeritute või nakatunute kohortides.  
4. TLR3 rs3775291 T-alleel omab kaitset HIV-i nakatumise eest KESN-ide 
seas. Kaitse võib olla vahendatud läbi TLR3, mis tuvastab viiruse genoomi 
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